Document:

tsla-ex104_231.htm

Exhibit 10.4

Confidential Treatment Requested by Tesla, Inc.

 

AMENDMENT NO. 4
TO
LOAN AND SECURITY AGREEMENT 

THIS AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of August 16, 2018, is entered into by and among LML WAREHOUSE SPV, LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto, the Group Agents party hereto, DEUTSCHE BANK TRUST COMPANY AMERICAS, a New York banking corporation, as paying agent (the “Paying Agent”) and DEUTSCHE BANK AG, NEW YORK BRANCH, as administrative agent (in such capacity, the “Administrative Agent”) and is made in respect of the Loan and Security Agreement, dated as of August 17, 2017, as amended on October 18, 2017, as further amended on March 23, 2018, as further amended on May 4, 2018 (the “Loan Agreement”) among the Borrower, Tesla Finance LLC, a Delaware limited liability company (“TFL”), the Lenders party thereto, the Group Agents party thereto, the Administrative Agent and the Paying Agent.  Defined terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Loan Agreement as amended hereby.

WHEREAS, the Borrower, the Lenders, the Group Agents, the Paying Agent and the Administrative Agent have agreed to amend the Loan Agreement on the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the premises set forth above, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Lenders, the Group Agents, the Paying Agent and the Administrative Agent agree as follows:

1.Amendments to Loan Agreement.  Effective as of the Amendment Effective Date (as defined below) and subject to the satisfaction of the conditions precedent set forth in Section 2 hereof:

(a)Section 1.01 of the Loan Agreement is hereby amended by adding the following definitions thereto in the appropriate alphabetical order:

“Amendment No. 4 Effective Date” shall mean August 16, 2018.

“Collateral Agency and Security Agreement” shall mean the Collateral Agency and Security Agreement, dated as of August 16, 2018, among the Trust, TFL and the Collateral Agent.

“Collateral Agent” means TLT Leasing Corp., a Delaware corporation.

“DB Supplemental Commitment” shall have the meaning specified in the Fee Letter.

“Recommenced TFL Facility Borrowing Date” shall mean the first TFL Loan Increase Date to occur after the Amendment No. 4 Effective Date.

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

“Required Supermajority Group Agents” shall mean at any time (a) if there are two or fewer Group Agents, then all Group Agents, and (b) if there are more than two Group Agents, (i) Group Agents for Lenders then holding more than sixty-six and two-thirds percent (66-2/3%) of the Commitments then in effect, or (ii) if the Commitments have terminated, Group Agents for Lenders then holding more than sixty-six and two-thirds percent (66-2/3%) of the Loans (Group Agents that are Affiliates of one another being considered as one Group Agent for purposes of this proviso). 

“Supermajority Terms” shall mean (i) the definition of “Base Residual Value”; (ii) the definition of “Change in Control”; (iii) the definition of “Credit Loss Ratio Trigger”; (iv) the definition of “Delinquency Ratio Trigger”; (v) the definition of “Eligible Lease”; (vi) the individual limits in the definition of “Excess Concentration Amount”; (vii) the definition of “Interest Rate Hedge Trigger Event”; (viii) the definition of “Mark-to-Market MRM Residual Value”; (ix) the definition of “Maximum Loan Balance”; (x) the definition of “Portfolio Performance Condition”; (xi) the definition of “Required Discount Rate”; (xii) the definition of “Required Reserve Account Balance”; (xiii) the definition of “Residual Value Loss Ratio Trigger”; (xiv) the definition of “Securitization Value”; (xv) the definition of “Servicer Default”; (xvi) the definition of “Tesla Change in Control”; (xvii) the definition of “Turbo Amortization Period”; (xviii) Section 2.04; (xix) Section 6.01(n); (xx) Section 6.03; and (xxi) Section 8.01.

(b)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Facility Limit” by replacing the reference to “$588,874,193.58” with “$1,100,000,000”. 

(c)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Fee Letter” to read as follows:

“Fee Letter” shall mean the Second Amended and Restated Fee Letter dated as of August 16, 2018 among the Borrower, the Administrative Agent, the Group Agents and the Lenders, setting forth the upfront fee and certain other fees and expenses payable to the Administrative Agent and the Lenders by the Borrower.

(d)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Loan Maturity Date” by replacing the reference to “September 2019” with “September 2020”.

(e)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Portfolio Performance Condition” by replacing the references to [***] in clause (ii) thereof and in clause (y) to the proviso thereof with [***].

(f)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Scheduled Expiration Date” by replacing the reference to “August 17, 2018” with “August 16, 2019”.

2

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(g)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Transaction Documents” to read as follows:

“Transaction Documents” shall mean the Trust Agreement, the Warehouse SUBI Supplement, the Warehouse SUBI Servicing Agreement, the LeaseDimensions Subservicing Agreement, the eVault Letter Agreement, the Warehouse SUBI Sale Agreement, this Agreement, the Collateral Agency and Security Agreement, the Fee Letter, each Loan Request, each Settlement Statement, each Notice of Warehouse SUBI Lease Allocation, each Interest Rate Hedge and each other agreement, report, certificate or other document delivered by any Tesla Party, Tesla, Inc. or TFL (other than in its capacity as managing member of LML) pursuant to or in connection with this Agreement.  For the avoidance of doubt, the TFL Transaction Documents, the LML Partnership Agreement and the LML SUBI Supplement shall not constitute Transaction Documents under this Agreement.

(h)Section 1.01 of the Loan Agreement is hereby amended by amending the definition of “Warehouse SUBI Collection Account” by replacing the reference to “Section 7.06(d)” with “Section 7.04(a)”.

(i)Section 2.11(b) of the Loan Agreement is hereby amended by deleting Section 2.11(b) in its entirety and inserting in lieu thereof a new Section 2.11(b) reading in its entirety as follows:

“(b)TFL may, at the written directions of the Borrower and TFL Borrower, reduce the Maximum Facility Limit subject to the following terms and conditions:

(i)TFL shall send a written notice (such notice, “Maximum Facility Limit Reduction Notice”) signed by an Authorized Signatory to the Administrative Agent (who shall forward the same to the Group Agents) and TFL Administrative Agent, which notice shall specify:

(A)the amount by which the Maximum Facility Limit is proposed to be reduced (the “Maximum Facility Limit Reduction Amount”) and whether such Maximum Facility Limit Reduction Amount is reducing the Maximum Facility Limit by the DB Supplemental Commitment; provided that, the resulting Maximum Facility Limit after taking into account the Maximum Facility Limit Reduction Amount shall not be less than the sum of the Loan Balance and the TFL Loan Balance on the Maximum Facility Limit Reduction Date;

(B)the date on which such reduction is proposed to occur (the “Maximum Facility Limit Reduction Date”), which Maximum Facility Limit Reduction Date shall be not less than five (5) Business Days after the date of such Maximum Facility Limit Reduction Notice; and

3

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(C)the amount of the Maximum Facility Limit Reduction Amount that shall reduce the Facility Limit and the TFL Facility Limit, respectively, provided that the Facility Limit shall not be less than the Loan Balance on the Maximum Facility Limit Reduction Date.

(ii)On each Maximum Facility Limit Reduction Date, the Facility Limit will be reduced by the amount specified in the related Maximum Facility Limit Reduction Notice and each such reduction shall reduce each Lender’s Commitment by its ratable share (based on the Commitments of the Lenders) of the Maximum Facility Limit Reduction Amount; provided, however, that if the Maximum Facility Limit Reduction Notice reduces the DB Supplemental Commitment, then such reduction shall only reduce Deutsche Bank AG, New York Branch’s Commitment and shall not reduce each Lender’s Commitment by its ratable share.

(iii)With respect to a reduction of the Maximum Facility Limit by the DB Supplemental Commitment, in order to cause each Lender to have its respective Commitment Percentage of the Loans on such Maximum Facility Limit Reduction Date (after giving effect to the decrease of the Maximum Facility Limit on such Maximum Facility Limit Reduction Date), each existing Lender shall sell, transfer and assign pursuant to one or more Assignment and Assumption Agreements, on such Maximum Facility Limit Reduction Date, the appropriate portion, if any, of its Loans, as applicable, to one or more Lenders such that each Lender’s Loan and Commitment, as applicable, will be proportionate to its Commitment Percentage as of such Maximum Facility Limit Reduction Date as determined by the Administrative Agent.

(iv)No reduction in the Maximum Facility Limit shall occur if after giving effect to such reduction and any repayments of the Loan Balance, the Facility Limit will be less than the Loan Balance.

On each Maximum Facility Limit Reduction Date, the Administrative Agent shall update its books and records to reflect the updated Maximum Facility Limit, Facility Limit and Commitment of each Lender.”

(j)Section 2.12(a)(iv) of the Loan Agreement is hereby amended by deleting Section 2.12(a)(iv) in its entirety and inserting in lieu thereof a new Section 2.12(a)(iv) reading in its entirety as follows:

“(iv)Following the Recommenced TFL Facility Borrowing Date, TFL may not reallocate any portion of the TFL Facility Limit to the Facility Limit without the prior written consent of all Group Agents.”

4

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(k)Section 2.12(b) of the Loan Agreement is hereby amended by deleting Section 2.12(b) in its entirety and inserting in lieu thereof a new Section 2.12(b) reading in its entirety as follows:

“(b)In addition, on the Recommenced TFL Facility Borrowing Date and on each Payment Date occurring after the Recommenced TFL Facility Borrowing Date, the excess of the Facility Limit over the aggregate principal amount of the Loans shall automatically be reallocated from the Facility Limit to the TFL Facility Limit.”

(l)Section 4.01(o) of the Loan Agreement is hereby amended by deleting Section 4.01(o) in its entirety and  inserting in lieu thereof a new Section 4.01(o) reading in its entirety as follows:

“(o) Good Title; Perfection.  Immediately prior to the pledge hereunder, the Borrower shall be the legal and beneficial owner of the Warehouse SUBI Certificate and the beneficial owner of the Warehouse SUBI Assets with respect thereto, free and clear of any Adverse Claim (other than the interest of the Collateral Agent under the Collateral Agency and Security Agreement).  This Agreement is effective to create, and shall transfer to the Administrative Agent a valid security interest in the Warehouse SUBI Certificate and the Borrower’s beneficial interest in the Warehouse SUBI Assets and Collections (to the extent provided by Section 9-315 of the UCC (or other section of similar content of the Relevant UCC) with respect thereto and in the other Collateral free and clear of any Adverse Claim (except as created by this Agreement and the Collateral Agency and Security Agreement), which security interest is perfected (except as to the Warehouse SUBI Leased Vehicles in which the Collateral Agent is noted as the lienholder on the related Certificate of Title) and of first priority.  On or prior to the Closing Date (and, with respect to Additional Warehouse SUBI Assets, on the applicable Warehouse SUBI Lease Allocation Date, including a Warehouse SUBI Lease Allocation Date which is a Loan Increase Date), all financing statements and other documents required to be recorded or filed in order to perfect and protect the Administrative Agent’s security interest in and to the Collateral against all creditors of and transferees from the Borrower will have been duly filed in each filing office necessary for such purpose (other than any notation of the security interest of the Administrative Agent on any Certificates of Title for Warehouse SUBI Leased Vehicles) and all filing fees and taxes, if any, payable in connection with such filings shall have been paid in full.  No effective financing statement or other instrument similar in effect covering any Collateral with respect thereto is on file in any recording office, except those filed pursuant to this Agreement or the Collateral Agency and Security Agreement.

(m)Section 5.02(d) of the Loan Agreement is hereby amended by replacing the reference to “At least two (2) Business Days” in the first sentence with “Not later than 12:00 p.m. New York City time on the Business Day”.

5

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(n)Section 6.01(l) of the Loan Agreement is hereby amended by deleting Section 6.01(l) in its entirety and  inserting in lieu thereof a new Section 6.01(l) reading in its entirety as follows:

“(l)Maintenance of Security Interests in Warehouse SUBI.  The Borrower shall take such steps as are necessary to preserve and maintain the security interest of the Administrative Agent (for the benefit of the Secured Parties) in the Warehouse SUBI and other Collateral as a valid and enforceable first priority perfected security interest, subject to no Adverse Claims (other than the interest of the Collateral Agent under the Collateral Agency and Security Agreement).”

(o)Section 6.02(b) of the Loan Agreement is hereby amended by deleting Section 6.02(b) in its entirety and  inserting in lieu thereof a new Section 6.02(b) reading in its entirety as follows:

“(b)Transfers, Liens, Etc.  Except for the Adverse Claims of the Administrative Agent created by this Agreement, of the Collateral Agent created by the Collateral Agency and Security Agreement and except for other transfers permitted under this Agreement, the Borrower shall not transfer, assign (by operation of law or otherwise) or otherwise dispose of, or create or suffer to exist any Adverse Claim (including the filing of any financing statement) upon or with respect to the Collateral (or any portion thereof), or upon or with respect to any account to which any Collections are sent, or assign any right to receive income in respect thereto.

(p)Section 6.02(e) of the Loan Agreement is hereby amended by deleting Section 6.02(b) in its entirety and  inserting in lieu thereof a new Section 6.02(b) reading in its entirety as follows:

“(e)Change to other Agreements.  The Borrower shall not (i) terminate, amend, supplement, modify or waive, or grant or consent to any such termination, amendment, waiver or consent, or permit to become effective any amendment, supplement, waiver or other modification to the Warehouse SUBI Servicing Agreement, the Warehouse SUBI Sale Agreement, the Warehouse SUBI Supplement, the Trust Agreement (except to the extent such termination, amendment, waiver or consent (i) relates solely to the UTI or a special unit of beneficial interest other than the Warehouse SUBI and (ii) does not have any adverse effect on the Lenders, the Administrative Agent or any other Secured Party, the Collateral or the SUBI Assets) or the eVault Letter Agreement, or (ii) terminate, amend, supplement, modify or waive, or grant or consent to any such termination, amendment, waiver or consent, or permit to become effective any amendment, supplement, waiver or other modification to any other Transaction Documents that could reasonably be expected to have a Material Adverse Effect, without, in each case, the consent of the Administrative Agent and the Required Group Agents (or the Required Supermajority Group Agents in the case of an amendment to the Warehouse SUBI Servicing Agreement that amends the definition of “Servicer Default”), in each case, such consents not to be unreasonably withheld, delayed or conditioned.”

6

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(q)Section 12.02(a) of the Loan Agreement is hereby amended by deleting Section 12.02(a) in its entirety and inserting in lieu thereof a new Section 12.02(a) reading in its entirety as follows:

“(a)No failure on the part of the Group Agents, the Conduit Lenders, the Committed Lenders, the Paying Agent or the Administrative Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right.  No amendment or waiver of any provision of this Agreement or consent to any departure by the Borrower or TFL therefrom shall be effective unless in a writing signed by the Administrative Agent and the Required Group Agents (and, in the case of any amendment, also signed by the Borrower and, if applicable, TFL), and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no amendment, waiver or consent that modifies any of the Supermajority Terms shall be effective unless in writing and signed by the Required Supermajority Group Agents; provided, further, however, that no such waiver, amendment, or consent shall, unless in writing and signed by the Group Agents for all the Lenders directly affected thereby (or by the Administrative Agent with the consent of the Group Agents for all the Lenders directly affected thereby), in addition to the Required Group Agents or Required Supermajority Group Agents, as the case may be, (or by the Administrative Agent with the consent of the Required Group Agents or Required Supermajority Group Agents, as the case may be) and Borrower and acknowledged by the Administrative Agent, do any of the following:

(i)increase or extend the Commitment of any Lender (or reinstate any Commitment terminated pursuant to Section 8.02(a));

(ii)postpone or delay any date fixed for, or waive, any scheduled installment of principal or any payment of interest (other than a waiver of the imposition of the default interest margin pursuant to the terms of the Transaction Documents), fees or other amounts due to the Lenders (or any of them) under any other Transaction Document;

(iii)reduce the principal of, or the rate of interest specified herein (other than a waiver of the imposition of the default interest margin pursuant to the terms of the Transaction Documents), or of any fees or other amounts payable hereunder or under any other Transaction Document;

(iv)change the percentage of the Commitments or of the aggregate unpaid principal amount of the Loans which shall be required for the Lenders or any of them to take any action hereunder;

(v)amend this Section 12.02 or the definition of “Required Group Agents” or the definition of “Supermajority Terms” or the definition of “Required Supermajority Group Agents” or any provision providing for consent or other action by all Lenders or amend the definition of “Commitment Percentage” or “Percentage;” or

7

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(vi)discharge TFL or any Tesla Party from its respective payment Secured Obligations under the Transaction Documents, or release all or substantially all of the Collateral, except as otherwise may be provided in this Agreement or the other Transaction Documents;

it being agreed that all Lenders shall be deemed to be directly affected by an amendment or waiver of the type described in the preceding clauses (iv), (v) and (vi).”

(r)Section 12.02(b) of the Loan Agreement is hereby amended by deleting Section 12.02(b) in its entirety and inserting in lieu thereof a new Section 12.02(b) reading in its entirety as follows:

“(b)No amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent, in addition to the Required Group Agents, the Required Supermajority Group Agents or the Group Agents for all Lenders directly affected thereby, as the case may be (or by the Administrative Agent with the consent of the Required Group Agents, the Required Supermajority Group Agents or the Group Agents for all the Lenders directly affected thereby, as the case may be), affect the rights or duties of the Administrative Agent, under this Agreement or any other Transaction Document.  No amendment, waiver or consent shall, unless in writing and signed by the Paying Agent, affect the rights or duties of the Paying Agent, under this Agreement or any other Transaction Documents.  No amendment, modification or waiver of this Agreement or any Transaction Document altering the ratable treatment of Secured Obligations arising under Eligible Interest Rate Hedges resulting in such Secured Obligations being junior in right of payment to principal of the Loans or resulting in Secured Obligations owing to any Eligible Interest Rate Hedge Provider becoming unsecured (other than releases of Liens permitted in accordance with the terms hereof), in each case in a manner adverse to any Eligible Interest Rate Hedge Provider, shall be effective without the written consent of such Eligible Interest Rate Hedge Provider.

(s)Schedule 8 of the Loan Agreement is hereby replaced in its entirety with Schedule 8 attached hereto.

2.Conditions Precedent. This Amendment shall become effective as of the date hereof (the “Amendment Effective Date”) upon satisfaction or waiver of the following conditions precedent:

(a)the receipt by the Administrative Agent or its counsel of counterpart signature pages to this Amendment and each other document and certificate to be executed or delivered in connection with this Amendment, as more fully described on Exhibit A hereto;

(b)each Group Agent shall have received, for the benefit of the Lenders in its related Group, the “Upfront Fee” in accordance with and as defined in the Second Amended and Restated Fee Letter, dated as of the date hereof, by and among the Borrower, the Group Agents and the Administrative Agent;

8

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

(c)no Default, Event of Default or Potential Servicer Default shall have occurred or be continuing, the Termination Date shall not have occurred and no Event of Bankruptcy shall have occurred with respect to TFL or Tesla, Inc.; and

(d)the Administrative Agent and each Group Agent shall have received such other documents, instruments and agreements as the Administrative Agent or such Group Agent may have reasonably requested.

3.Representations and Warranties of the Borrower.  The Borrower hereby represents and warrants to the Administrative Agent, each Group Agent and each Lender as of the date hereof that:

(a)This Amendment and the Loan Agreement, as amended hereby, constitute the legal, valid and binding obligations of the Borrower and are enforceable against the Borrower in accordance with their respective terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws relating to or limiting creditors’ rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or at law).

(b)Upon the effectiveness of this Amendment, the Borrower hereby affirms that all representations and warranties made by it in Article IV of the Loan Agreement, as amended, are correct in all material respects on the date hereof as though made as of the effective date of this Amendment, unless and to the extent that any such representation and warranty is stated to relate solely to an earlier date, in which case such representation and warranty shall have been true and correct in all material respects as of such earlier date.

(c)As of the date hereof, no Default, Event of Default or Potential Servicer Default shall have occurred or be continuing, the Termination Date shall not have occurred and no Event of Bankruptcy shall have occurred with respect to TFL or Tesla, Inc.

4.Reference to and Effect on the Loan Agreement.

(a)Upon the effectiveness of Section 1 hereof, each reference in the Loan Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import shall mean and be a reference to the Loan Agreement as amended hereby.

(b)The Loan Agreement, as amended hereby, and all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect until hereafter terminated in accordance with their respective terms, and the Loan Agreement and such documents, instruments and agreements are hereby ratified and confirmed.

(c)Except as expressly provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent, any Agent or any Lender, nor constitute a waiver of any provision of the Loan Agreement or any other documents, instruments and agreements executed and/or delivered in connection therewith.

9

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

5.Costs and Expenses.  The Borrower agrees to pay all reasonable and actual costs, fees, and out‐of‐pocket expenses (including the reasonable attorneys’ fees, costs and expenses of Sidley Austin LLP, counsel to the Administrative Agent, the Group Agents and the Lenders) incurred by the Administrative Agent, each Group Agent and each Lender in connection with the preparation, review, execution and enforcement of this Amendment.

6.Cessation of Bank of America, N.A. as Committed Lender and Group Agent.  

(a)The parties hereto acknowledge and agree that, effective as of the Amendment Effective Date and subject to receipt of the Expiration Amount (as hereinafter defined), Bank of America, N.A, as Group Agent (the “Non-Continuing Agent”) and as Committed Lender (the “Non-Continuing Committed Lender”), shall cease to be a party to the Loan and Security Agreement and shall have no further rights, duties or obligations thereunder or under any other Transaction Documents (except any such rights, duties or obligations which by the express terms thereof survive the termination of the Loan and Security Agreement or such other Transaction Document or the resignation or termination of a Group Agent or a Lender).  The Borrower shall pay or cause to be paid, by wire transfer of immediately available funds, to the Non-Continuing Agent for its own account and for the account of the Non-Continuing Committed Lender an amount equal to $45,802,048.22 (the “Expiration Amount”), representing all accrued and unpaid Unused Fees and other Secured Obligations owing to the Non-Continuing Agent and the Non-Continuing Committed Lender on August 16, 2018.

(b)Each of the Non-Continuing Agent and the Non-Continuing Committed Lender acknowledges that the Expiration Amount constitutes the total of all outstanding principal and all accrued and unpaid interest, fees and expenses and other Secured Obligations payable to the Non-Continuing Agent or the Non-Continuing Committed Lender, as applicable, as of August 16, 2018 under the Loan and Security Agreement and the other Transaction Documents.

(c)The Non-Continuing Agent acknowledges and agrees that notwithstanding the terms of that certain Amended and Restated Fee Letter, dated as of October 18, 2017 (the “Existing Fee Letter”), by and among the Borrower, the Non-Continuing Agent, the Administrative Agent and the other Group Agents and Lenders party thereto, the consent of the Non-Continuing Agent shall not be required in order to amend, restate, supplement or otherwise modify, or waive any provision of or provide any consent under, the Existing Fee Letter.

10

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

7.Consent to Amendment of Warehouse SUBI Servicing Agreement.  By execution of this Amendment, the Borrower, the Administrative Agent and the Lenders hereby consent to Amendment No. 1 to 2017-A Warehouse SUBI Servicing Agreement, dated the date hereof, among Tesla Lease Trust, TFL, as Servicer, and Wells Fargo Bank, National Association, as Back-Up Servicer.

8.GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO ITS CONFLICTS OF LAWS PROVISIONS (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

9.Headings.  Section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose.

10.Counterparts.  This Amendment may be executed by one or more of the parties to the Amendment on any number of separate counterparts and all of said counterparts taken together shall be deemed to constitute one and the same instrument.  Delivery of an executed counterpart of a signature page to this Amendment by facsimile (transmitted by telecopier or by email) shall be effective as delivery of a manually executed counterpart of this Amendment.

Remainder of page left intentionally blank

 

 

11

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by their duly authorized signatories as of the date first above written.

 

	
LML WAREHOUSE SPV, LLC,

	
as Borrower

	
 
	
 
	
 

	
By:
	
 
	
/s/ Yaron Klein

	
Name:
	
 
	
Yaron Klein

	
Title:
	
 
	
Authorized Signatory

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
DEUTSCHE BANK TRUST COMPANY AMERICAS,

	
as Paying Agent

	
 
	
 
	
 

	
By:
	
 
	
/s/ Diana Vasconez

	
Name:
	
 
	
Diana Vasconez

	
Title:
	
 
	
Assistant Vice President

	
 
	
 
	
 

	
By:
	
 
	
/s/ Mark Esposito

	
Name:
	
 
	
Mark Esposito

	
Title:
	
 
	
Assistant Vice President

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
DEUTSCHE BANK AG, NEW YORK BRANCH,

	
as Administrative Agent, as a Group Agent and as

	
a Committed Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Katherine Bologna

	
Name:
	
 
	
Katherine Bologna

	
Title:
	
 
	
Managing Director

	
 
	
 
	
 

	
By:
	
 
	
/s/ Kevin Fagan

	
Name:
	
 
	
Kevin Fagan

	
Title:
	
 
	
Vice President

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
CITIBANK, N.A.,

	
as a Group Agent and as a Committed Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Brian Chin

	
Name:
	
 
	
Brian Chin

	
Title:
	
 
	
Vice President

	
 
	
 
	
 

	
CAFCO, LLC,

	
as Conduit Lender

	
 

	
By:
	
 
	
Citibank, N.A., as Attorney-in-Fact

	
 
	
 
	
 

	
By:
	
 
	
/s/ Linda Moses

	
Name:
	
 
	
Linda Moses

	
Title:
	
 
	
Vice President

	
 
	
 
	
 

	
CHARTA, LLC,

	
as Conduit Lender

	
 
	
 
	
 

	
By:
	
 
	
Citibank, N.A., as Attorney-in-Fact

	
 
	
 
	
 

	
By:
	
 
	
/s/ Linda Moses

	
Name:
	
 
	
Linda Moses

	
Title:
	
 
	
Vice President

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
CIESCO, LLC,

	
as Conduit Lender

	
 

	
By:
	
 
	
Citibank, N.A., as Attorney-in-Fact

	
 
	
 
	
 

	
By:
	
 
	
/s/ Linda Moses

	
Name:
	
 
	
Linda Moses

	
Title:
	
 
	
Vice President

	
 
	
 
	
 

	
CRC FUNDING, LLC,

	
as Conduit Lender

	
 
	
 
	
 

	
By:
	
 
	
Citibank, N.A., as Attorney-in-Fact

	
 
	
 
	
 

	
By:
	
 
	
/s/ Linda Moses

	
Name:
	
 
	
Linda Moses

	
Title:
	
 
	
Vice President

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
BANK OF AMERICA, N.A.,

	
as a Non-Continuing Agent and as a Non-Continuing Committed Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Christopher C. Jonas

	
Name:
	
 
	
Christopher C. Jonas

	
Title:
	
 
	
Director

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
ROYAL BANK OF CANADA,

	
as a Group Agent and as a Committed Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Angela Nimoh-Etsiakoh

	
Name:
	
 
	
Angela Nimoh-Etsiakoh

	
Title:
	
 
	
Authorized Signatory

	
 
	
 
	
 

	
By:
	
 
	
/s/ Sofia Shields

	
Name:
	
 
	
Sofia Shields

	
Title:
	
 
	
Authorized Signatory

	
 
	
 
	
 

	
LAKESHORE TRUST,

	
as a Conduit Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Nur Khan

	
Name:
	
 
	
Nur Khan

	
Title:
	
 
	
Authorized Signatory

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
CREDIT SUISSE AG, NEW YORK BRANCH,

	
as a Group Agent

	
 
	
 
	
 

	
By:
	
 
	
/s/ Patrick Duggan

	
Name:
	
 
	
Patrick Duggan

	
Title:
	
 
	
Vice President

	
 
	
 
	
 

	
By:
	
 
	
/s/ Jeffrey Traola

	
Name:
	
 
	
Jeffrey Traola

	
Title:
	
 
	
Director

	
 
	
 
	
 

	
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH,

	
as a Committed Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ Patrick Duggan

	
Name:
	
 
	
Patrick Duggan

	
Title:
	
 
	
Vice President

	
 
	
 
	
 

	
By:
	
 
	
/s/ Jeffrey Traola

	
Name:
	
 
	
Jeffrey Traola

	
Title:
	
 
	
Director

	
 
	
 
	
 

	
GIFS CAPITAL COMPANY LLC,

	
as a Conduit Lender

	
 
	
 
	
 

	
By:
	
 
	
/s/ R. Scott Chisholm

	
Name:
	
 
	
R. Scott Chisholm

	
Title:
	
 
	
Authorized Signer

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

 

	
BARCLAYS BANK PLC,

	
as a Group Agent

	
 
	
 
	
 

	
By:
	
 
	
/s/ John McCarthy

	
Name:
	
 
	
John McCarthy

	
Title:
	
 
	
Director

	
 
	
 
	
 

	
SALISBURY RECEIVABLES COMPANY LLC,

	
as a Conduit Lender

	
 
	
 
	
 

	
By: Barclays Bank PLC, as attorney-in-fact

	
 
	
 
	
 

	
By:
	
 
	
/s/ John McCarthy

	
Name:
	
 
	
John McCarthy

	
Title:
	
 
	
Director

 

 

Signature Page to Amendment No. 4 to Loan and Security Agreement

 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

 

 

Confidential Treatment Requested by Tesla, Inc.

EXHIBIT A

LIST OF DOCUMENTS AND CERTIFICATES

TO BE DELIVERED ON THE AMENDMENT EFFECTIVE DATE

 

	
 
	
Document

	
1.
	
Amendment No. 4 to Loan and Security Agreement

	
2.
	
Second Amended and Restated Fee Letter

	
3.
	
Amendment No. 1 to 2017-A Warehouse SUBI Servicing Agreement

	
4.
	
Collateral Agency and Security Agreement

	
5.
	
Amendment No. 4 to TFL Warehouse Agreement

	
6.
	
Third Amended and Restated Fee Letter for TFL Warehouse Agreement

	
7.
	
Amendment No. 1 to Warehouse SUBI Servicing Agreement

	
8.
	
Joinder Agreement to the Collateral Agency and Security Agreement for the benefit of the secured parties under the Loan and Security Agreement

	
9.
	
Joinder Agreement to the Collateral Agency and Security Agreement for the benefit of the secured parties under 2014 Warehouse Agreement

	
10.
	
UCC-1 Financing Statement naming Tesla Lease Trust, as Debtor, and TLT Leasing Corp., as Secured Party

	
11.
	
UCC-1 Financing Statement naming Tesla Finance LLC, as Debtor, and TLT Leasing Corp., as Secured Party

	
12.
	
Opinion of Katten Muchin Rosenman LLP with respect to certain security interest matters under the Collateral Agency and Security Agreement

 

 

Ex. A-1

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.

Confidential Treatment Requested by Tesla, Inc.

Schedule 8

to Loan and Security Agreement

Commitments of Lenders

 

	
Committed Lender
	
 
	
Commitment
	
 

	
Deutsche Bank AG, New York Branch
	
 
	
$
	
400,000,000.00
	
 

	
Citibank, N.A.
	
 
	
$
	
300,000,000.00
	
 

	
Credit Suisse AG, Cayman Islands Branch
	
 
	
$
	
135,000,000.00
	
 

	
Royal Bank of Canada
	
 
	
$
	
132,500,000.00
	
 

	
Barclays Bank PLC
	
 
	
$
	
132,500,000.00
	
 

	
Total:
	
 
	
$
	
100,000,000.00
	
 

 

Schedule 8-1

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions.Exhibit 10.2

    

     

    

    
      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH
        THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

      

      EXECUTION COPY

      

      

      CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT

       

      by and between

       

      Merck Sharp & Dohme B.V.,

       

      and

       

      Rexahn Pharmaceuticals, Inc.

       

      
        
          

      

      
      TABLE OF CONTENTS

       

      	 	 	 	
              Page

            
	 	 	 	 
	
              1.

            	
              DEFINITIONS.

            	
              1

            
	 	 	 
	
              2.

            	
              SCOPE OF THE AGREEMENT

            	
              9

            
	 	
              2.1

            	
              Generally

            	
              9

            
	 	
              2.2

            	
              Manufacturing Delay

            	
              9

            
	 	
              2.3

            	
              Compound Commitments

            	
              9

            
	 	
              2.4

            	
              Delegation of Obligations

            	
              9

            
	 	
              2.5

            	
              Compounds

            	
              10

            
	 	 	 	 
	
              3.

            	
              CONDUCT OF THE STUDY

            	
              10

            
	 	
              3.1

            	
              Sponsor

            	
              10

            
	 	
              3.2

            	
              Performance

            	
              10

            
	 	
              3.3

            	
              Debarred Personnel; Exclusions Lists

            	
              10

            
	 	
              3.4

            	
              Regulatory Matters

            	
              11

            
	 	
              3.5

            	
              Documentation

            	
              11

            
	 	
              3.6

            	
              Copies

            	
              11

            
	 	
              3.7

            	
              Sample Testing

            	
              11

            
	 	
              3.8

            	
              Ownership and Use of Clinical Data.

            	
              12

            
	 	
              3.9

            	
              Regulatory Submission

            	
              12

            
	 	
              3.10

            	
              Joint Development Committee; Alliance Managers

            	
              12

            
	 	
              3.11

            	
              Certain Memoranda and Reports

            	
              13

            
	 	
              3.12

            	
              Relationship

            	
              14

            
	 	
              3.13

            	
              Licensing

            	
              14

            
	 	
              3.14

            	
              [***]

            	
              14

            
	 	 	 	 
	
              4.

            	
              PROTOCOL, STATISTICAL ANALYSIS PLAN AND INFORMED CONSENT; CERTAIN COVENANTS

            	
              15

            
	 	
              4.1

            	
              Protocol and Statistical Analysis Plan

            	
              15

            
	 	
              4.2

            	
              Informed Consent

            	
              15

            
	 	
              4.3

            	
              Financial Disclosure

            	
              16

            
	 	
              4.4

            	
              Transparency Reporting.

            	
              16

            
	 	 	 	 
	
              5.

            	
              ADVERSE EVENT REPORTING.

            	
              17

            
	 	
              5.1

            	
              Pharmacovigilance Agreement

            	
              17

            
	 	
              5.2

            	
              Transmission of SAEs

            	
              17

            
	 	 	 	 
	
              6.

            	
              TERM AND TERMINATION.

            	
              17

            
	 	
              6.1

            	
              Term

            	
              17

            
	 	
              6.2

            	
              Merck Termination for Safety

            	
              17

            
	 	
              6.3

            	
              Termination for Material Breach

            	
              18

            
	 	
              6.4

            	
              Termination for Patient Safety

            	
              18

            
	 	
              6.5

            	
              Termination for Regulatory Action; Other Reasons

            	 18

            
	 	
              6.6

            	
              Termination related to Anti-Corruption Obligations

            	 18

            

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        i

        
          

      

      	 	
              6.7

            	
              Return of Merck Compound

            	18
	 	
              6.8

            	
              Survival

            	 19

            
	 	
              6.9

            	
              No Prejudice

            	19
	 	
              6.10

            	
              Confidential Information

            	
              19

            
	 	
              6.11

            	
              Manufacturing Costs

            	19
	 	 	 	 
	
              7.

            	
              COSTS OF STUDY.

            	19
	 	 	 
	
              8.

            	
              SUPPLY AND USE OF THE COMPOUNDS.

            	
              19

            
	 	
              8.1

            	
              Supply of the Compounds

            	19
	 	
              8.2

            	
              Clinical Quality Agreement

            	
              20

            
	 	
              8.3

            	
              Minimum Shelf Life Requirements

            	
              20

            
	 	
              8.4

            	
              Provision of Compounds

            	
              20

            
	 	
              8.5

            	
              Labeling and Packaging; Use, Handling and Storage

            	
              21

            
	 	
              8.6

            	
              Product Specifications

            	
              21

            
	 	
              8.7

            	
              Changes to Manufacturing

            	
              21

            
	 	
              8.8

            	
              Product Testing; Noncompliance

            	
              21

            
	 	
              8.9

            	
              Investigations

            	
              23

            
	 	
              8.10

            	
              Shortage; Allocation

            	
              23

            
	 	
              8.11

            	
              Records; Audit Rights

            	
              23

            
	 	
              8.12

            	
              Quality

            	
              23

            
	 	
              8.13

            	
              Quality Control

            	
              23

            
	 	
              8.14

            	
              Audits and Inspections

            	
              23

            
	 	
              8.15

            	
              Recalls

            	
              23

            
	 	
              8.16

            	
              VAT

            	
              23

            
	 	 	 	 
	
              9.

            	
              CONFIDENTIALITY.

            	
              25

            
	 	
              9.1

            	
              Confidential Information

            	
              25

            
	 	
              9.2

            	
              Inventions

            	
              25

            
	 	
              9.3

            	
              Personal Identifiable Data

            	25
	 	 	 	 
	
              10.

            	
              INTELLECTUAL PROPERTY.

            	
              25

            
	 	
              10.1

            	
              [***].

            	25
	 	
              10.2

            	
              Inventions Owned by Rexahn

            	26
	 	
              10.3

            	
              Inventions Owned by Merck

            	
              27

            
	 	
              10.4

            	
              Mutual Freedom to Operate for Combination Inventions

            	
              27

            
	 	
              10.5

            	
              Ownership of Other Inventions

            	
              27

            
	 	 	 	 
	
              11.

            	
              REPRINTS; RIGHTS OF CROSS-REFERENCE

            	
              27

            
	 	 	 
	
              12.

            	
              PUBLICATIONS; PRESS RELEASES.

            	
              28

            
	 	
              12.1

            	
              Clinical Trial Registry

            	
              28

            
	 	
              12.2

            	
              Publication

            	
              28

            
	 	
              12.3

            	
              Press Releases

            	28
	 	 	 	 
	
              13.

            	
              REPRESENTATIONS AND WARRANTIES; DISCLAIMERS.

            	
              28

            
	 	
              13.1

            	
              Due Authorization

            	28
	 	
              13.2

            	
              Compounds

            	
              29

            

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        ii

        
          

      

      	 	
              13.3

            	
              Results

            	29
	 	
              13.4

            	
              Anti-Corruption and Anti-Bribery

            	
              29

            
	 	
              13.5

            	
              DISCLAIMER

            	
              31

            
	 	 	 	 
	
              14.

            	
              INSURANCE; INDEMNIFICATION; LIMITATION OF LIABILITY

            	
              
                31

              

            
	 	
              14.1

            	
              Insurance

            	
              
                31

              

            
	 	
              14.2

            	
              Indemnification

            	
              32

            
	 	
              14.3

            	
              LIMITATION OF LIABILITY

            	
              32

            
	 	 	 	 
	
              15.

            	
              USE OF NAME

            	
              33

            
	 	 	 
	
              16.

            	
              FORCE MAJEURE

            	
              33

            
	 	 	 
	
              17.

            	
              ENTIRE AGREEMENT; AMENDMENT; WAIVER

            	
              33

            
	 	 	 
	
              18.

            	
              ASSIGNMENT AND AFFILIATES

            	
              33

            
	 	 	 
	
              19.

            	
              INVALID PROVISION

            	
              34

            
	 	 	 
	
              20.

            	
              NO ADDITIONAL OBLIGATIONS

            	
              34

            
	 	 	 
	
              21.

            	
              GOVERNING LAW; DISPUTE RESOLUTION

            	
              34

            
	 	 	 
	
              22.

            	
              NOTICES

            	
              34

            
	 	 	 
	
              23.

            	
              RELATIONSHIP OF THE PARTIES

            	 35

            
	 	 	 
	
              24.

            	
              COUNTERPARTS AND DUE EXECUTION

            	 36

            
	 	 	 
	
              25.

            	
              CONSTRUCTION

            	 36

            

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        iii

        
          

      

      
        Exhibits

        

        

        Exhibit  A – Protocol Synopsis

        Exhibit  B  – Supply of Compound

        Exhibit  C  – Rexahn Press Release

        

        

        	
                Schedules

              	 

              
	
                Schedule I

              	
                Data Sharing and Sample Testing Schedule

              
	
                Schedule 2.4

              	
                Rexahn Third Parties

              

        

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        iv

        
          

      

      
      CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT

       

      This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of the date of last signature hereunder (the “Effective Date”), by and between Merck Sharp &
          Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands (“Merck”), and Rexahn Pharmaceuticals, Inc., having a place of business
          at 15245 Shady Grove Road, Suite 455, Rockville, MD 20850, United States (“Rexahn”).  Merck and Rexahn are each referred to herein individually as “Party” and collectively as “Parties”.

       

      RECITALS

       

      A.            Merck holds intellectual property rights with respect to the Merck Compound (as defined below).

       

      B.            Rexahn is developing the Rexahn Compound (as defined below) for the treatment of certain tumor
          types.

       

      C.            Merck is developing the Merck Compound for the treatment of certain tumor types.

       

      D.            Rexahn desires to sponsor a clinical trial in which the Rexahn Compound and the Merck Compound
          would be dosed concurrently or in combination.

       

      E.             Merck and Rexahn, consistent with the terms of this Agreement, desire to collaborate as more
          fully described herein, including by providing the Merck Compound and the Rexahn Compound for the Study (as defined below).

       

       NOW, THEREFORE, in consideration of the premises and of the following mutual promises, covenants and conditions, the Parties,
          intending to be legally bound, mutually agree as follows:

       

      1.             Definitions.

       

      For all purposes of this Agreement, the capitalized terms defined in this Article 1 and throughout this Agreement shall have the meanings herein
          specified.

       

      1.1           “Affiliate” means, with respect to either Party, a person, firm, corporation, partnership or other entity that, now or hereafter, directly or indirectly owns or controls
          said Party, or, now or hereafter, is owned or controlled by said Party, or is under common ownership or control with said Party.  The word “control” as used in this definition means (a) the direct or indirect ownership of fifty percent (50%) or
          more of the outstanding voting securities of a legal entity, or (b) possession, directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities, contract rights,
          voting rights, corporate governance or otherwise.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        1

        
          

      

      

      1.2           “Agreement” means this agreement, as amended by the Parties from time to time, and as set forth in the preamble.

       

      1.3           “Alliance Manager” has the meaning set forth in Section 3.10.3.

       

      1.4            “Applicable Law” means all federal, state, local, national and regional statutes, laws, rules, regulations and directives applicable to a particular activity hereunder,
          including performance of clinical trials, medical treatment and the processing and protection of personal and medical data, that may be in effect and/or updated from time to time, including those promulgated by the United States Food and Drug
          Administration (“FDA”), national regulatory authorities, the European Medicines Agency (“EMA”) and any successor agency to the FDA or EMA or any agency or authority performing some or all of the functions of the FDA or EMA in any jurisdiction outside the United States or the European Union
          (each a “Regulatory Authority” and collectively, “Regulatory Authorities”), and including cGMP and GCP (each
          as defined below); all data protection requirements such as those specified in the EU General Data Protection Regulation and the regulations issued under the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”); export control and economic sanctions regulations which prohibit the shipment of United States-origin products and technology to certain
          restricted countries, entities and individuals; anti-bribery and anti-corruption laws pertaining to interactions with government agents, officials and representatives; laws and regulations governing payments to healthcare providers; securities
          laws, rules and regulations including that of the Securities and Exchange Commission (“SEC”) or similar governmental agency in the United States or
          abroad; and any country’s or jurisdiction’s successor or replacement statutes, laws, rules, regulations and directives relating to the foregoing.

       

      1.5            “Business Day” means any day other than a Saturday, Sunday, or a day on which commercial banks located in the country where the applicable obligations are to be performed
          are authorized or required by law to be closed.

       

      1.6            “cGMP” means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities that may be in effect
          from time to time and are applicable to the Manufacture of the Compounds.

       

      1.7           “Clinical Data” means all data (including raw data) and results [***] generated by or on behalf of either Party or at either Party’s direction, or by or on behalf of the
          Parties together or at their direction, in the course of each such Party’s performance of the Study.

       

      1.8           “Clinical Quality Agreement” has the meaning set forth in Section 8.2.

       

      1.9           “CMC” means “Chemistry Manufacturing and Controls” as such term of art
          is used in the pharmaceutical industry.

       

      1.10         “Combination” means the use or method of using the Rexahn Compound and the Merck Compound in concomitant and/or sequential administration.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        2

        
          

      

      

      1.11         [***].

       

      1.12         “Compounds” means the Rexahn Compound and the Merck Compound.  A “Compound” means either the Rexahn Compound or the Merck Compound, as applicable.

       

      1.13         “Confidential Information” means any information, Know-How or other proprietary information or materials furnished to one Party (“Receiving Party”) by or on behalf of the
          other Party (“Disclosing Party”) in connection with this Agreement, except to the extent that such information or materials: (a) was already known
          to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party, as demonstrated by competent evidence; (b) was generally available to the public or otherwise part of the public domain
          at the time of its disclosure to the Receiving Party; (c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this
          Agreement; (d) was disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others; or (e) was subsequently developed by the Receiving Party without use of the Disclosing
          Party Confidential Information, as demonstrated by competent evidence.

       

      1.14         [***].

       

      1.15         “Control” or “Controlled” means, with respect to particular information or
          intellectual property, that the applicable Party owns or has a license to such information or intellectual property and has the ability to grant a right, license or sublicense to the other Party as provided for herein without violating the terms
          of any agreement or other arrangement with any Third Party.

       

      1.16         “CTA” means an application to a Regulatory Authority for purposes of requesting the ability to start or continue a clinical trial.

       

      1.17         “Data Sharing and Sample Testing Schedule” means the schedule attached hereto as Schedule I.

       

      1.18        “Defending Party” has the meaning set forth in Section 14.2.3.

       

      1.19        “Delivery” with respect to the Merck Compound has the meaning set forth in Section 8.4.1, and with respect to the
          Rexahn Compound has the meaning set forth in Section 8.4.2.

       

      1.20         [***].

       

      1.21         “Disclosing Party” has the meaning set forth in the definition of Confidential Information.

       

      1.22         “Effective Date” has the meaning set forth in the preamble.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        3

        
          

      

      

      1.23         “EMA” has the meaning set forth in the definition of Applicable Law.

       

      1.24         “European Union” means the European Union, as its membership may be constituted from time to time, and any successor
          thereto.

       

      1.25         “Excluded Merck Results” has the meaning set forth in Schedule I.

       

      1.26         “Exclusions List” has the meaning set forth in the definition of Violation.

       

      1.27         “FDA” has the meaning set forth in the definition of Applicable Law.

       

      1.28         [***].

      

      1.29         “Final Study Report” has the meaning set forth in Section 3.11.2.

       

      1.30         “Force Majeure” has the meaning set forth in Article 16.

       

      1.31         “GAAP” has the meaning set forth in Section 6.11.

       

      1.32         “GCP” means the Good Clinical Practices officially published by EMA, FDA and the International Conference on Harmonisation of Technical Requirements for Registration of
          Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the testing of the Compounds.

       

      1.33         “Government Official” means: (a) any officer or employee of a government or any department, agency or instrument of a government; (b) any Person acting in an official capacity
          for or on behalf of a government or any department, agency, or instrument of a government; (c) any officer or employee of a company or business owned in whole or part by a government; (d) any officer or employee of a public international
          organization such as the World Bank or United Nations; (e) any officer or employee of a political party or any Person acting in an official capacity on behalf of a political party; and/or (f) any candidate for political office; who, when such
          Government Official is acting in an official capacity, or in an official decision-making role, has responsibility for performing regulatory inspections, government authorizations or licenses, or otherwise has the capacity to make decisions with
          the potential to affect the business of either of the Parties.

       

      1.34         “HIPAA” has the meaning set forth in the definition of Applicable Law.

       

      1.35         “IND” means any Investigational New Drug Application filed or to be filed with the FDA as described in Title 21 of the U.S. Code of Federal Regulations, Part 312, and the
          equivalent application in the jurisdictions outside the United States, including an “Investigational Medicinal Product Dossier” filed or to be filed with Regulatory Authorities in the European Union.

       

      1.36         [***].

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        4

        
          

      

      

      1.37         “Inventions” means all inventions and discoveries, whether or not patentable, that are made, conceived, or first actually reduced to practice by or on behalf of a Party, or by
          or on behalf of the Parties together, (a) in the design or performance of the Study or in the design or performance of any [***]; (b) through use of unpublished [***] Clinical Data; or (c) or through use of Sample Testing Results that are shared between the Parties pursuant to the Data Sharing and Sample Testing Schedule.

       

      1.38         “Joint Development Committee” or “JDC” has the meaning set forth in Section 3.10.1.

       

      1.39         [***].

       

      1.40         [***].

       

      1.41         [***].

       

      1.42         “Know-How” means any proprietary invention, innovation, improvement, development, discovery, computer program, device, trade secret, method, know-how, process, technique or the
          like, including manufacturing, use, process, structural, operational and other data and information, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or
          copyrightable, that is not generally known or otherwise in the public domain.

       

      1.43         “Liability” has the meaning set forth in Section 14.2.1.

       

      1.44         “Manufacture,” “Manufactured,” or “Manufacturing” means all activities related to the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste
          disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch and supply, as applicable.

       

      1.45         “Manufacturer’s Release” or “Release” has the meaning ascribed to such term
          in the Clinical Quality Agreement.

       

      1.46         “Manufacturing Site” means the facilities where a Compound is Manufactured by or on behalf of a Party, as such Manufacturing Site may change from time to time in accordance
          with Section 8.7.

       

      1.47         “Merck” has the meaning set forth in the preamble.

       

      1.48         “Merck Background Patents” has the meaning set forth in Section 10.4.2.

       

      1.49         “Merck Compound” means pembrolizumab, a humanized anti-human PD-1 monoclonal antibody[***].

       

      1.50         “Merck Inventions” has the meaning set forth in Section 10.3.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      

      
        5

        
          

      

      

      1.51         “NDA” means a New Drug Application, Biologics License Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the United States Federal Food,
          Drug and Cosmetic Act, or similar application or submission for a marketing authorization of a product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in that country or in
          that group of countries.

      

      1.52         “Non-Conformance” means, with respect to a given unit of Compound, (a) an event that deviates from an approved cGMP requirement with respect to the applicable Compound, such as
          a procedure, Specification, or operating parameter, or that requires an investigation to assess impact to the quality of the applicable Compound, or (b) that such Compound failed to meet the applicable representations and warranties set forth in
          Section 2.3.  Classification of the Non-Conformance is detailed in the Clinical Quality Agreement.

       

      1.53         [***].

       

      1.54         [***].

       

      1.55         “Other Party” has the meaning set forth in Section 14.2.3.

       

      1.56         “Party” has the meaning set forth in the preamble.

       

      1.57         “Patent” means a patent, extension, registration, supplementary protection certificate or the like that issues from a given Patent Application.

       

      1.58         “Patent Application” means a patent application (including any provisional, substitution, divisional, continuation, continuation in part, reissue, renewal, reexamination,
          extension, supplementary protection certificate and the like) in respect of a given invention.

       

      1.59         “PD-1 Antagonist” means any small or large molecule that [***].

       

      1.60         “Person” means any individual, sole proprietorship, partnership, corporation, business trust, joint stock company, trust, unincorporated organization, association, limited
          liability company, institution, public benefit corporation, joint venture, entity or governmental entity.

       

      1.61         “Pharmacovigilance Agreement” has the meaning set forth in Section 5.1.

       

      1.62         “Project Manager” has the meaning set forth in Section 3.10.1.

      

      1.63         “Protocol” means the written documentation that describes the Study and sets forth specific activities to be performed as part of the conduct of the Study.

       

      1.64         “Receiving Party” has the meaning set forth in the definition of Confidential Information.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        6

        
          

      

      

      1.65         “Regulatory Approvals” means, with respect to a Compound or a Combination and a country, any and all permissions (other than the Manufacturing approvals) required to be
          obtained from Regulatory Authorities and any other competent authority for the development, registration, importation, use (including use in clinical trials), distribution, sale and marketing of such Compound or Combination in such country,
          including any pricing or reimbursement approvals (even if not legally required to sell Compound or Combination).

       

      1.66         “Regulatory Authorities” has the meaning set forth in the definition of Applicable Law.

       

      1.67         “Regulatory Documentation” means, with respect to a Compound (or Compounds), all submissions to Regulatory Authorities in connection with the development of such Compound(s),
          including all INDs and amendments thereto, NDAs and amendments thereto, drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse event files, complaint files, inspection reports and manufacturing
          records, in each case together with all supporting documents (including documents that include Clinical Data).

       

      1.68         “Related Agreements” means the Pharmacovigilance Agreement and the Clinical Quality Agreement.

       

      1.69         “Rexahn” has the meaning set forth in the preamble.

       

      1.70         “Rexahn Background Patents” has the meaning set forth in Section 10.4.1.

       

      1.71         “Rexahn Class Compound” means any small or large molecule inhibitor of phosphorylated p-68.

       

      1.72         “Rexahn Compound” means RX-5902 (SupinoxinTM), [***].

       

      1.73         “Rexahn Inventions” has the meaning set forth in Section 10.2

       

      1.74         “Right of Reference” means the “right of reference” defined in 21 CFR 314.3(b), including with regard to a Party, allowing the applicable Regulatory Authority in a country to
          have access to relevant information (by cross-reference, incorporation by reference or otherwise) contained in Regulatory Documentation (and any data contained therein) filed with such Regulatory Authority with respect to a Party’s Compound, only
          to the extent necessary for the conduct of the Study in such country or as otherwise expressly permitted or required under this Agreement to enable a Party to exercise its rights or perform its obligations hereunder.

       

      1.75         “SAEs” has the meaning set forth in Section 5.2.

       

      1.76         “Sample Testing” means the analyses to be performed by each Party using the applicable Samples, as described in the Data Sharing and Sample Testing Schedule.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        7

        
          

      

      1.77         “Sample Testing Results” means those data and results arising from the Sample Testing performed by a Party [***].

      

      

      1.78         “Samples” means biological specimens collected from subjects participating in the Study, including urine, blood and tissue samples.

       

      1.79         “Specifications” means, with respect to a given Compound, the set of requirements for such Compound as set forth in the Clinical Quality Agreement.

       

      1.80         “Study” means the Phase II clinical trial described in the Protocol to evaluate the safety, pharmacokinetics, pharmacodynamics, and/or preliminary efficacy of the concomitant
          and/or sequential administration of the combination of the Merck Compound and the Rexahn Compound in patients with metastatic Triple Negative Breast Cancer (TNBC) and described herein in Exhibit A.

       

      1.81         “Study Completion” means database lock of the Study results.

       

      1.82         “Subcontractors” has the meaning set forth in Section 2.4.

       

      1.83         [***].

       

      1.84         [***].

       

      1.85         [***].

       

      1.86         “Term” has the meaning set forth in Section 6.1.

       

      1.87         “Third Party” means any Person or entity other than Rexahn, Merck or their respective Affiliates.

       

      1.88         “Third Party Infringement” has the meaning set forth in Section 10.1.2(a).

       

      1.89         “Third Party Study” has the meaning set forth in Section 3.14.1.

       

      1.90         [***].

       

      1.91         “Toxicity & Safety Data” means all clinical adverse event information and/or
          patient-related safety data included in the Clinical Data, as more fully described in the Pharmacovigilance Agreement.

       

      1.92         “VAT” has the meaning set forth in Section 8.16.1.

       

      1.93         “Violation” means that a Party or any of its officers or directors or any other personnel (or other permitted agents of a Party performing activities hereunder) has been:  (a)
          convicted of any of the felonies identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website, including 42 U.S.C. 1320a-7(a)
          (http://oig.hhs.gov/exclusions/authorities.asp); (b) identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in the System for Award Management
          (http://www.sam.gov); or (c) listed by any US Federal agency as being suspended, proposed for debarment, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a
          (http://www.fda.gov/ora/compliance_ref/debar/) ((a), (b) and (c) collectively the “Exclusions Lists”).

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

      
        8

        
          

      

      

      
        
          2.             Scope of the Agreement.

           

            

        

      

      2.1           Generally.  Each Party shall: (a) contribute to the Study such resources as are necessary to fulfill its obligations set forth in this Agreement; and (b) act in good faith in performing
          its obligations under this Agreement and each Related Agreement to which it is a Party.

       

      2.2           Manufacturing Delay. Each Party shall notify the other Party as promptly as possible in the event of any Manufacturing delay that is likely to adversely affect supply of its Compound as
          contemplated by this Agreement.

       

      2.3           Compound

              Commitments.

       

      2.3.1          Rexahn agrees to Manufacture
          and supply the Rexahn Compound for purposes of the Study in accordance with Article 8, and Rexahn hereby represents and warrants to Merck that, at the time of
          Delivery of the Rexahn Compound, such Rexahn Compound shall have been Manufactured and supplied in compliance with: (a) the Specifications for the Rexahn Compound; (b) the Clinical Quality Agreement; and (c) all Applicable Law, including cGMP and
          health, safety and environmental protections.

       

      2.3.2          Merck agrees to Manufacture
          and supply the Merck Compound for purposes of the Study in accordance with Article 8, and Merck hereby represents and warrants to Rexahn that, at the time of
          Delivery of the Merck Compound, such Merck Compound shall have been Manufactured and supplied in compliance with: (a) the Specifications for the Merck Compound; (b) the Clinical Quality Agreement; and (c) all Applicable Law, including cGMP and
          health, safety and environmental protections.

       

      2.3.3          Without limiting the
          foregoing, each Party is responsible for obtaining all regulatory approvals (including facility licenses) that are required to Manufacture its Compound in accordance with Applicable Law (provided that, for clarity, Rexahn shall be responsible for obtaining Regulatory Approvals for the Study as set forth in Section

              3.4).

       

      2.4           Delegation of Obligations.  Each Party shall have the right to delegate any portion of its obligations hereunder as follows:  (a) to such Party’s Affiliates; (b) to Third Parties to the
          extent related to the Manufacture of such Party’s Compound; and (c) to Third Parties upon the other Party’s prior written consent (such consent not to unreasonably withheld).  [***]  Any and all Third Parties to whom a Party delegates any of its
          obligations hereunder are referred to as “Subcontractors”.  Notwithstanding any delegation of its obligations hereunder, each Party shall remain solely and fully liable for the performance of its Affiliates and Subcontractors to which such Party
          delegates the performance of its obligations under this Agreement.  Each Party shall ensure that each of its Affiliates and Subcontractors performs such Party’s obligations pursuant to the terms of this Agreement, including the Appendices and
          Schedules attached hereto.  Each Party shall use reasonable efforts to obtain and maintain copies of documents relating to the obligations performed by such Affiliates and Subcontractors that are required to be provided to the other Party under
          this Agreement.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        9

        
          

      

      2.5           Compounds.  This Agreement does not create any obligation on the part of Merck to provide the Merck Compound for any activities other than the Study, nor does it create any obligation on
          the part of Rexahn to provide the Rexahn Compound for any activities other than the Study.

       

      
        
          3.             Conduct of the Study.

           

            

        

      

      3.1           Sponsor.  Rexahn shall act as the sponsor of the Study under its own IND for the Rexahn Compound with a Right of Reference to the IND of the Merck Compound, as necessary, as further
          described in Section 3.4; provided, however, that in no event shall Rexahn file an additional IND for the Study unless required by Regulatory Authorities to do so.  If a Regulatory Authority requests
          an additional IND for the Study, the Parties shall meet and mutually agree on an approach to address such requirement.

       

      3.2           Performance.  Rexahn shall ensure that the Study is performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP.

       

      3.3           Debarred Personnel; Exclusions Lists.  Notwithstanding anything to the contrary contained herein, neither Party shall employ or subcontract with any Person that is excluded, debarred,
          suspended, proposed for suspension or debarment, in Violation or otherwise ineligible for government programs for the performance of any activities under this Agreement or the Related Agreements.  Each Party hereby certifies that it has not
          employed or otherwise used in any capacity and will not employ or otherwise use in any capacity, the services of any Person suspended, proposed for debarment, or debarred under United States law, including 21 USC 335a, or any foreign equivalent
          thereof, in performing any activities under this Agreement or the Related Agreements and that such Party has, as of the Effective Date, screened itself, and its officers and directors, against the Exclusions Lists and that it has informed the
          other Party whether it or any of its officers or directors has been in Violation.  Each Party shall notify the other Party in writing immediately if any such suspension, proposed debarment, debarment or Violation occurs or comes to its attention,
          and shall, with respect to any Person so suspended, proposed for debarment, debarred or in Violation, promptly remove such Person from performing in any capacity related to activities under this Agreement or the Related Agreements.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        10

        
          

      

      3.4           Regulatory Matters.  Rexahn shall:  (a) obtain, prior to initiating the Study, all Regulatory Approvals from all Regulatory Authorities, ethics committees and/or institutional review
          boards with jurisdiction over the Study; and (b) [***] follow all directions from any such Regulatory Authorities, ethics committees and/or institutional review boards.  Merck shall have the right (but not the obligation) to participate in any
          discussions (including meetings) with a Regulatory Authority regarding matters related to the Study and the Merck Compound and to collaborate on questions posed to Regulatory Authorities regarding the design and conduct of the Study.  If a Right
          of Reference is necessary for the conduct of the Study or for seeking Regulatory Approvals involving the Study, each Party shall provide to the other Party a cross-reference letter or similar communication to the applicable Regulatory Authority
          if needed to effectuate the Right of Reference.  Notwithstanding anything to the contrary in this Agreement, neither Party shall have any right to access the other Party’s CMC data with respect to such other Party’s Compound.  Merck shall
          authorize FDA and other applicable Regulatory Authorities to cross-reference the appropriate Merck Compound INDs and CTAs to provide data access to Rexahn sufficient to support conduct of the Study.  If Merck’s CTA is not available in a given
          country, Merck will file its CMC data with the Regulatory Authority for such country, referencing Rexahn’s CTA as appropriate (however, Rexahn shall have no right to directly access the CMC data).

       

      3.5           Documentation.  Rexahn shall maintain reports with respect to the Study and all related documentation in good scientific manner and in compliance with Applicable Law.  Rexahn shall
          provide to Merck all Study information and documentation reasonably requested by Merck to enable Merck to (a) comply with any of its legal, regulatory and/or contractual obligations, or respond to any request by any Regulatory Authority, in each
          case related to the Merck Compound, and (b) determine whether the Study has been performed in accordance with this Agreement.

       

      3.6           Copies.  Rexahn shall provide to Merck copies of all Clinical Data, in electronic form or other mutually agreeable alternate form and on the timelines specified in the Data Sharing and
          Sample Testing Schedule (if applicable) or upon mutually agreeable timelines; provided, however, that a complete copy of the Clinical Data shall be provided to Merck no later than [***] following Study Completion.  Rexahn shall ensure that (a) all patient authorizations and consents
          required under HIPAA, the EU General Data Protection Regulation or any other similar Applicable Law in connection with the Study permit such sharing of Clinical Data with Merck, and (b) it complies with any applicable safe harbor under Applicable
          Law related to transferring personal data in connection with sharing the Clinical Data, including by entering into a data protection agreement after the Effective Date but prior to initiation of clinical activities under the Study.

       

      3.7           Sample

              Testing.

       

      3.7.1         Rexahn shall provide Samples
          to Merck as specified in the Protocol or as agreed to by the Joint Development Committee.  Each Party shall (a) use the Samples only for the Sample Testing, and (b) conduct the Sample Testing assigned to such Party on the Data Sharing and Sample
          Testing Schedule solely in accordance with the Data Sharing and Sample Testing Schedule and the Protocol.  All Sample Testing Results shall be [***] under the Sample Testing Results.  If such assignment cannot or does not occur, including in
          circumstances where such assignment is precluded by Applicable Law, the Party with the obligation to assign hereby grants the other Party [***].  Excluded Merck Results shall be solely owned by Merck.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        11

        
          

      

      3.7.2          [***] Merck shall provide to
          Rexahn the Sample Testing Results for the Sample Testing conducted by or on behalf of Merck, in electronic form or other mutually agreeable [***]

       

      3.7.3          [***] Rexahn shall provide to
          Merck the Sample Testing Results for the Sample Testing conducted by or on behalf of Rexahn, in electronic form or other mutually agreeable alternate form, on the timelines specified in the Data Sharing and Sample Testing Schedule or [***].

       

      3.8           Ownership and Use of Clinical Data.

       

      3.8.1          All Clinical Data shall be
          jointly owned by Rexahn and Merck. [***].

       

      3.8.2          Notwithstanding the
          foregoing, [***] provided, however, that the
          foregoing shall not limit or restrict either Party’s ability to (i) use or disclose the Clinical Data as may be necessary to comply with Applicable Law or with such Party’s internal policies and procedures with respect to pharmacovigilance and
          adverse event reporting, or (ii) share with Third Parties or Affiliates Toxicity and Safety Data where because of severity, frequency or lack of reversibility either Party needs to use such Toxicity and Safety Data with respect to its own
          Compound or the Combination to ensure patient safety.  The Parties will furthermore consult and cooperate fully with each other on the provisions of this Agreement to be redacted in any filings required to be made by the Parties with the
          Securities and Exchange Commission or similar governmental agency in the U.S. or abroad, or as otherwise required by Applicable Law to protect to the fullest extent possible the Confidential Information of the Parties.

       

      3.8.3          Notwithstanding anything to the contrary in this Section 3.8, [***].

       

      3.8.4          If either Party desires to
          [***] which is not in accordance with this Section 3.8, such [***] shall require: (A) the advanced written consent of the other Party (which shall be at such
          Party’s sole discretion); and (B) such Third Party must be under obligations of confidentiality and non-use at least as stringent as those set forth in Section 9.1
          of this Agreement.

       

      3.9           Regulatory Submission.  It is understood and acknowledged by the Parties that positive Clinical Data could be used to obtain label changes for the Compounds, and each Party may propose a
          [***] in connection therewith in accordance with Section 3.14.

       

      3.10         Joint
              Development Committee; Alliance Managers.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        12

        
          

      

      3.10.1        The Parties shall form a
          joint development committee (the “Joint Development Committee” or “JDC”) made up of an equal number of representatives of Merck and Rexahn, which shall have responsibility for coordinating all regulatory and other activities under, and pursuant to, this Agreement.  The JDC will
          review and finalize the Protocol in accordance with Section 4.1. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties with respect to the Study and shall
          be a member of the JDC.  Other JDC members will be agreed by both Parties.

       

      3.10.2        The JDC shall meet as soon as
          practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study.  The JDC may meet in person or by means
          of teleconference, Internet conference, videoconference or other similar communications equipment.  Prior to any such meeting, Rexahn’s Project Manager shall provide an update in writing to Merck’s Project Manager, which update shall contain
          information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis (if results available) and other information relevant to the conduct of the Study.

       

      3.10.3        In addition to a Project
          Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication
          between the Parties and the effective exchange of information and shall serve as the primary point of contact for any issues arising under this Agreement.  The Alliance Managers shall have the right to attend all JDC meetings and may bring to the
          attention of the JDC any matters or issues either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree in writing.

       

      3.10.4        In the event that an issue
          arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue [***] or if there is a decision to be made by the JDC on which the members of the JDC cannot unanimously agree [***], the issue shall be
          elevated to the Vice President of Clinical Oncology for Merck and the Chief Executive Officer for Rexahn, who shall confer and use good faith efforts to reach a resolution or consensus.  In the event such escalation does not result in resolution
          or consensus [***]: (a) Merck shall have final decision-making authority with respect to issues related to the Merck Compound; and (b) Rexahn shall have final decision-making authority with respect to issues related to the Rexahn Compound [***]. 
          Notwithstanding the foregoing, neither the JDC nor either Party, in the exercise of their final decision-making authority, shall have any power to amend or modify the terms or provisions of this Agreement unless such amendment is duly authorized
          and executed in writing by authorized signatories of both Parties.

       

      3.11         Certain Memoranda and Reports.  Without limiting any other provision of this Agreement requiring Rexahn to provide to Merck documentation related to the Study, Rexahn shall provide to
          Merck drafts and final versions of the top-line results memorandum and final study report for the Study as described below.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS
          FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

       

      

      
        13

        
          

      

      

      3.11.1        Top-Line Results Memo.  Promptly following Study Completion, Rexahn shall provide to Merck an electronic draft of the top-line results memorandum
          for the Study, and Merck shall have [***] to provide comments thereon. Rexahn shall consider in good faith any comments provided by Merck on such draft top-line results memorandum and shall not include any statements therein relating to the Merck
          Compound that have not been approved by Merck.  Rexahn shall deliver to Merck a final version of the top-line results memorandum promptly following finalization thereof.

       

      3.11.2        Final Study Report.  Rexahn shall provide Merck with an electronic draft of the final study report promptly, but in no case later than [***] following Study Completion, and Merck shall [***]
          to provide comments thereon.  Rexahn shall consider in good faith any comments provided by Merck on the draft final study report and shall not include any statements therein relating to the Merck Compound that have not been approved by Merck. 
          Rexahn shall deliver to Merck a final version of the final study report promptly following finalization thereof (the “Final Study Report”).

       

      3.12         Relationship.  Except as expressly set forth in this Agreement, nothing in this Agreement shall: (a) prohibit either Party from performing clinical studies other than the Study relating
          to its own Compound, either individually or in combination with any other compound or product, in any therapeutic area; or (b) create an exclusive relationship between the Parties with respect to any Compound. Each Party acknowledges and agrees
          that nothing in this Agreement shall be construed as a representation or inference that the other Party will not develop for itself, or enter into business relationships with other Third Parties regarding, any products, programs, studies
          (including combination studies), technologies or processes that are similar to or that may compete with the Combination or any other product, program, technology or process, including with respect to Rexahn Class Compounds or PD-1 Antagonists, provided that [***] are not used or disclosed in connection therewith in violation of this Agreement.

       

      3.13         Licensing.  Nothing in this Agreement shall prohibit or restrict a Party from licensing, assigning or otherwise transferring to an Affiliate or Third Party such Party’s Compound or any
          Inventions, [***], owned solely by such Party. A Party may license, assign or transfer to an Affiliate or Third Party such Party’s interest in the [***], and in connection therewith share the shared Sample Testing Results owned by the other
          Party, solely to the extent such licensee, assignee or transferee agrees in writing to be bound by the terms of this Agreement with respect to such [***] and shared Sample Testing Results.  For purposes of clarity, any assignment or transfer of
          this Agreement must comply with Section 18 of this Agreement.

       

      3.14         [***].

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        14

        
          

      

      
        
          4.             Protocol, Statistical Analysis Plan and Informed Consent; Certain Covenants.

           

            

        

      

      4.1           Protocol and Statistical Analysis Plan.  A synopsis of the initial Protocol for the Study has been agreed to by the Parties as of the Effective Date and is attached hereto as Exhibit A. 
          Through the JDC, Rexahn shall (a) provide any draft versions of the Protocol or statistical analysis plan (and any subsequent revisions thereof) to Merck for Merck’s review and comment, (b) consider in good faith any changes to the draft Protocol
          or statistical analysis plan requested by Merck, and (c) incorporate any changes requested by Merck with respect to the Merck Compound.  Any proposed final version of the Protocol [***] having any amendment from that of Exhibit A related to the
          Merck Compound) or statistical analysis plan shall be submitted by Rexahn to the JDC for final approval.  To the extent the JDC cannot agree unanimously on the Protocol or statistical analysis submitted for final approval: (i) Rexahn shall have
          final decision-making authority with respect to matters in the Protocol or statistical analysis plan related to [***] (ii) Merck shall have final decision-making authority with respect to matters in the Protocol or statistical analysis plan
          related to [***] and (iii) all other matters in respect of the Protocol or statistical analysis plan on which the JDC cannot agree shall be resolved in accordance with Section

            3.10.4.  Once the final Protocol has been
          approved in accordance with this Section 4.1, any material changes to such approved final Protocol or statistical analysis plan (other than material changes
          relating solely to the Rexahn Compound) and any changes to the final Protocol (whether or not material) or statistical analysis plan relating to the Merck Compound shall require Merck’s prior written consent.  Any such proposed changes will be
          sent in writing to Merck’s Project Manager and Merck’s Alliance Manager.  Merck will provide such consent, or a written explanation for why such consent is being withheld, [***] of receiving a copy of Rexahn’s requested changes.

       

      4.1.1          Notwithstanding anything to
          the contrary contained herein, Merck, in its sole discretion, shall have the sole right to determine the dose and dosing regimen for the Merck Compound and shall have the final decision on all matters relating to the Merck Compound (including
          quantities of Merck Compound to be supplied pursuant to Article 8) and any information regarding the Merck Compound included in the Protocol.

       

      4.1.2          Notwithstanding anything to
          the contrary contained herein, Rexahn, in its sole discretion, shall have the sole right to determine the dose and dosing regimen for the Rexahn Compound and shall have the final decision on all matters relating to the Rexahn Compound (including
          quantities of Rexahn Compound to be supplied pursuant to Article 8) and any information regarding the Rexahn Compound included in the Protocol.

       

      4.2           Informed Consent.  Rexahn shall prepare the patient informed consent form for the Study (which shall include provisions regarding the use of Samples in Sample Testing) in consultation
          with Merck (it being understood and agreed that the portion of the informed consent form relating to the Sample Testing of the Merck Compound shall be provided to Rexahn by Merck).  Any proposed changes to such form that relate to the Merck
          Compound, including Sample Testing of the Merck Compound, shall be subject to Merck’s prior written consent.  Any such proposed changes will be sent in writing to Merck’s Project Manager and Merck’s Alliance Manager. Merck will provide such
          consent, or a written explanation for why such consent is being withheld, within [***]

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        15

        
          

      

      4.3           Financial Disclosure.  Rexahn shall (a) track and collect financial disclosure information from all “clinical investigators” involved in the Study and (b) prepare for submission (and
          submit as applicable) the certification and/or disclosure of the same in accordance with all Applicable Law, including, but not limited to, Part 54 of Title 21 of the United States Code of Federal Regulations (Financial Disclosure by Clinical
          Investigators) and related FDA Guidance Documents. Prior to the initiation of clinical activities under the Study, but in any event [***] the Parties shall determine whether Rexahn shall track and collect from all “clinical investigators”
          involved in the Study separate certification and/or disclosure forms for each of Merck and Rexahn or one (1) “combined” certification and/or disclosure form for both Merck and Rexahn. For purposes of this Section 4.3, the term “clinical investigators” shall have the meaning set forth in Part 54.2(d) of Title 21 of the United States Code of Federal Regulations.

       

      4.4           Transparency Reporting.

       

      4.4.1          With respect to any annual
          reporting period in which Rexahn is not an entity that is required to make a Transparency Report under Applicable Law, Rexahn will: (a) notify Merck, in writing, [***] that Rexahn is not so required; and (b) during such reporting period Rexahn
          will track and provide to Merck data regarding payments or other transfers of value by Rexahn to health care providers and health care professionals, but only to the extent such payments or other transfers of value were required, instructed,
          directed or otherwise caused by Merck pursuant to this Agreement in the format requested by Merck and provided on a basis to be agreed upon by both Parties.  Rexahn represents and warrants that any data provided by Rexahn to Merck pursuant to Section 4.4.1(b) above will be complete and accurate to the best of Rexahn’s knowledge.

       

      4.4.2          With respect to any annual
          reporting period in which Rexahn is required to make a Transparency Report under Applicable Law, Rexahn will provide to Merck, in writing, Rexahn’s point of contact for purposes of receiving information from Merck pursuant to this Section 4.4, along with such contact’s full name, email address, and telephone number. Rexahn may update such contact from time to time by notifying Merck in writing pursuant to Section 22 (Notices).  Where applicable, Merck will provide to such Rexahn contact all information regarding the value of the Merck Compound provided for use in the Study and any
          other information that may be required for Rexahn to satisfy its obligations under Applicable Law for such reporting.  In the event that the value of the Merck Compound provided pursuant to this Section 4.4.2 changes, Merck shall notify Rexahn of such revised value and the effective date thereof.

       

      4.4.3          For purposes of this Section 4.4, “Transparency Report” means a transparency report
          in connection with reporting payments and other transfers of value made to health care providers or health care professionals, including, as applicable and without limitation, Study sites, investigators, steering committee members, data
          monitoring committee members, and consultants in connection with the Study in accordance with reporting requirements under Applicable Law, including, without limitation, the Physician Payment Sunshine Act and state gift laws, and the European
          Federation of Pharmaceutical Industries and Associations Disclosure Code, or a Party’s applicable policies.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        16

        
          

      

      5.             Adverse

              Event Reporting.

       

      5.1           Pharmacovigilance Agreement.  Rexahn will be solely responsible for compliance with all Applicable Laws pertaining to safety reporting to the Rexahn IND for the Study.  The Parties (or
          their respective Affiliates) will execute a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) prior to the initiation of clinical
          activities under the Study, but in any event [***] to ensure the exchange of relevant safety data within appropriate timeframes and in an appropriate format to enable the Parties to fulfill local and international regulatory reporting obligations
          and to facilitate appropriate safety reviews.  In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement, the terms of this Agreement shall control. The Pharmacovigilance Agreement will include
          safety data exchange procedures governing the coordination of collection, investigation, reporting, and exchange of information concerning any adverse experiences, pregnancy reports, and any other safety information arising from or related to the
          use of the Merck Compound and Rexahn Compound in the Study, consistent with Applicable Law.  Such guidelines and procedures shall be in accordance with, and enable the Parties and their Affiliates to fulfill, local and international regulatory
          reporting obligations to Regulatory Authorities.

       

      5.2           Transmission of SAEs.  Rexahn will transmit to Merck all serious adverse events (“SAEs”)
          as follows:

       

      5.2.1          For drug-related fatal and
          life-threatening SAEs, Rexahn will send a processed case (on a CIOMS-1 form in English) [***] by Rexahn of such SAEs.

       

      5.2.2          For all other SAEs, including
          non-drug-related fatal and life-threatening SAEs, Rexahn will send a processed case (on a CIOMS-1 form in English) [***] by Rexahn of such SAEs.

       

      6.             Term and Termination.

       

      6.1           Term.  The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect until delivery of the Final Study Report by Rexahn to Merck, unless
          terminated earlier by either Party pursuant to this Article 6 (the “Term”).

       

      6.2           Merck Termination for Safety.  In the event that Merck in good faith believes that the Merck Compound is being used in the Study in an unsafe
          manner, Merck shall provide written notice thereof to Rexahn including a detailed description of the reasons for Merck’s concerns and any changes to the Protocol or other actions as applicable, requested by Merck in order to address such
          concerns.  If Rexahn fails to, promptly after receipt of Merck’s written notice, incorporate changes into the Protocol requested by Merck to address such issue [***] or to otherwise address such issue reasonably and in good faith, Merck may
          terminate this Agreement and the supply of the Merck Compound immediately upon written notice to Rexahn.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        17

        
          

      

      

      6.3           Termination for Material Breach.  Either Party may terminate this Agreement if the other Party commits a material breach of this Agreement, and such material breach continues for [***]
          from the non-breaching Party; provided that if such material breach cannot reasonably be cured [***] the breaching Party shall be given a
          reasonable period of time to cure such breach; provided further, that if such material breach is incapable of cure, then the notifying Party may terminate this Agreement effective after the expiration of such [***].

       

      6.4           Termination for Patient Safety.  If either Party determines in good faith, based on a review of the Clinical Data, or other Study-related Know-How or other information, that the Study may
          unreasonably affect patient safety, such Party shall promptly notify the other Party of such determination.  The Party receiving such notice may propose modifications to the Study to address the safety issue identified by the other Party and, if
          the notifying Party agrees, shall act to implement immediately such modifications; provided, however, that if the notifying Party, in its sole discretion, believes that there is imminent danger to patients, such Party need not wait for the other Party to propose modifications and
          may instead terminate this Agreement immediately upon written notice to such other Party.  Furthermore, if the notifying Party, in its sole discretion, believes that any modifications proposed by the other Party will not resolve the patient
          safety issue, such Party may terminate this Agreement effective upon written notice to such other Party.

       

      6.5           Termination for Regulatory Action; Other Reasons.  Either Party may terminate this Agreement immediately upon written notice to the other Party in the event that any Regulatory Authority
          takes any action, or raises any objection, that prevents the terminating Party from supplying its Compound for purposes of the Study or that any Regulatory Authority revokes or suspends the Regulatory Approvals necessary to conduct the Study or
          requires that the Study be terminated or suspended.  Additionally, either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party in the event that it determines in its sole discretion to withdraw
          any applicable Regulatory Approval for its Compound or to discontinue development of its Compound, for medical, scientific or legal reasons.

       

      6.6           Termination related to Anti-Corruption Obligations.  Either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party, if such other Party
          fails to perform any of its obligations under Section 13.4 or breaches any representation or warranty contained in Section 13.4.  Except as set forth in Section 6.11, the non-terminating Party shall have no claim against the
          terminating Party for compensation for any loss of whatever nature by virtue of the termination of this Agreement in accordance with this Section 6.6.

       

      6.7           Return of Merck Compound.  In the event that this Agreement is terminated, or in the event Rexahn remains in possession (including through any Affiliate or Subcontractor) of Merck
          Compound at the time this Agreement expires, Rexahn shall, at Merck’s sole discretion, promptly either return or destroy all unused Merck Compound pursuant to Merck’s instructions.  If Merck requests that Rexahn destroy the unused Merck Compound,
          Rexahn shall provide written certification of such destruction.  Notwithstanding the foregoing, (a) in the event this Agreement is terminated by Merck pursuant to Section

              6.2, Section 6.3 or Section 6.6 and Merck requests that
          all unused Merck Compound be returned or destroyed, Rexahn shall promptly return to Merck or destroy the unused Merck Compound [***], or (b) in the event this Agreement is terminated by Rexahn pursuant to Section 6.3 or Section 6.6 and Merck requests that all unused Merck Compound be returned or destroyed, Rexahn shall promptly return to Merck or destroy the unused Merck Compound [***].

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        18

        
          

      

      

      6.8           Survival.  The provisions of Sections 3.4 through 3.8 (inclusive), 3.13, 3.14,
          6.7 through 6.11 (inclusive), 8.5.2, 8.11, 8.14
          through 8.16 (inclusive), 12.2, 13.4.6,
          13.5, 14.2, and 14.3, and Articles 1, 5, 9 through 12 (inclusive), 17, and 20 through 25 (inclusive) shall survive the expiration or
          termination of this Agreement.

       

      6.9           No Prejudice.  Termination of this Agreement shall be without prejudice to any claim or right of action of either Party against the other Party for any prior breach of this Agreement.

       

      6.10         Confidential Information.  Upon termination of this Agreement, each Party and its Affiliates shall promptly return to the Disclosing Party or destroy any Confidential Information of the
          Disclosing Party [***] furnished to the Receiving Party by the Disclosing Party; provided, however that the Receiving Party may retain one copy of such Confidential Information in its confidential files, solely for purposes of exercising the Receiving Party’s rights hereunder,
          satisfying its obligations hereunder or complying with any legal proceeding or requirement with respect thereto, and provided further that the
          Receiving Party shall not be required to erase electronic files created in the ordinary course of business during automatic system back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own
          general electronic files and information so long as such electronic files are (a) maintained only on centralized storage servers (and not on personal computers or devices), (b) not accessible by any of its personnel (other than its information
          technology specialists), and (c) are not otherwise accessed subsequently except with the written consent of the Disclosing Party or as required by law or legal process.  Such retained copies of Confidential Information shall remain subject to the
          confidentiality and non-use obligations herein.

       

      6.11         Manufacturing Costs.  [***].

       

      7.             Costs of Study.

       

      The Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (b) [***]; and (c) Rexahn shall bear[***]other costs associated with the conduct of the Study[***].

       

      8.            Supply and Use of the Compounds.

       

      8.1           Supply of the Compounds.  Subject to the terms and conditions of this Agreement, each of Rexahn and Merck will use commercially reasonable efforts to supply, or cause to be supplied, the
          quantities of its respective Compound as are set forth in Exhibit B, on the timelines set forth in Exhibit B, in each case for use in the Study; provided,

            however, that no Merck Compound shall be Delivered until after an IND has been obtained by Rexahn in accordance with Section 3.1.  If the Protocol is
          changed in accordance with Article 4 in such a manner that may affect the quantities of Compound to be provided or the timing for providing such quantities,
          the Parties shall amend Exhibit B to reflect any changes required to be consistent with the Protocol.  Each Party shall also provide to the other Party a contact person for the supply of its Compound under this Agreement.  Notwithstanding the
          foregoing, or anything to the contrary herein, in the event that a Party is: (a) not supplying its Compound in accordance with the terms of this Agreement, then the other Party shall have no obligation to supply its Compound; or (b) allocating
          under Section 8.10, then the other Party may allocate proportionally.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      

      
        19

        
          

      

      

      8.2           Clinical Quality Agreement.  Within [***] days after the Effective Date of this Agreement, but in any event before any supply of Merck Compound hereunder, the Parties (or their respective
          Affiliates) shall enter into a quality agreement that shall address and govern issues related to the quality of clinical drug supply to be supplied by the Parties for use in the Study (the “Clinical Quality Agreement”).  In the event of any inconsistency between the terms of this Agreement and the Clinical Quality Agreement, the terms of this Agreement shall control. The Clinical Quality
          Agreement shall, among other things:  (a) detail classification of any Compound found to have a Non-Conformance; (b) include criteria for Manufacturer’s Release and related certificates and documentation; (c) include criteria and timeframes for
          acceptance of Merck Compound; (d) include procedures for the resolution of disputes regarding any Compounds found to have a Non-Conformance; and (e) include provisions governing the recall of Compounds.

       

      8.3           Minimum Shelf Life Requirements.  Each Party shall use commercially reasonable efforts to supply its Compound hereunder with an adequate remaining shelf life at the time of Delivery to
          meet the Study requirements.

       

      8.4           Provision

              of Compounds.

       

      8.4.1          Merck will, at its own cost,
          deliver the Merck Compound [***] to Rexahn’s, or its designee’s, location as specified by Rexahn (“Delivery” with respect to such Merck Compound). 
          Title and risk of loss for the Merck Compound shall transfer from Merck to Rexahn at Delivery.  All costs associated with the subsequent transportation, warehousing and distribution of Merck Compound shall be borne by Rexahn.  Rexahn will, or
          will cause its designee to: (a) take delivery of the Merck Compound supplied hereunder; (b) perform the acceptance (including testing) procedures allocated to it under the Clinical Quality Agreement; (c) subsequently label and pack the Merck
          Compound (in accordance with Section 8.5), and promptly ship the Merck Compound to the Study sites for use in the Study, in compliance with cGMP, GCP and
          other Applicable Law and the Clinical Quality Agreement; and (d) provide, from time to time at the reasonable request of Merck, the following information: any applicable chain of custody forms, in-transport temperature recorder(s), records and
          receipt verification documentation, such other transport or storage documentation as may be reasonably requested by Merck, and usage and inventory reconciliation documentation related to the Merck Compound.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        20

        
          

      

      8.4.2          Rexahn is solely responsible,
          at its own cost, for supplying (including all Manufacturing, acceptance and release testing) the Rexahn Compound for the Study, and the subsequent handling, storage, transportation, warehousing and distribution of the Rexahn Compound supplied
          hereunder.  Rexahn shall ensure that all such activities are conducted in compliance with cGMP, GCP and other Applicable Law and the Clinical Quality Agreement.  For purposes of this Agreement, the “Delivery” of a given quantity of the Rexahn Compound shall be deemed to occur when such quantity is packaged for shipment to a Study site.

       

      8.5           Labeling

              and Packaging; Use, Handling and Storage.

       

      8.5.1          The Parties’ obligations with
          respect to the labeling and packaging of the Compounds are as set forth in the Clinical Quality Agreement.  Notwithstanding the foregoing or anything to the contrary contained herein, Merck shall provide the Merck Compound to Rexahn in the form
          of unlabeled vials, and Rexahn shall be responsible for labeling, packaging and leafleting such Merck Compound in accordance with the terms and conditions of the Clinical Quality Agreement and otherwise in accordance with all Applicable Law,
          including cGMP, GCP, and health, safety and environmental protections.

       

      8.5.2          Rexahn shall: (a) use the
          Merck Compound solely for purposes of performing the Study; (b) not use the Merck Compound in any manner that is inconsistent with this Agreement or for any commercial purpose; and (c) label, use, store, transport, handle and dispose of the Merck
          Compound in compliance with Applicable Law and the Clinical Quality Agreement, as well as all written instructions of Merck.  Rexahn shall not
          reverse engineer, reverse compile, disassemble or otherwise attempt to derive the composition or underlying information, structure or ideas of the Merck Compound, and in particular shall not analyze the Merck Compound by physical, chemical or
          biochemical means except as necessary to perform its obligations under the Clinical Quality Agreement.

       

      8.6           Product Specifications.  A certificate of analysis shall accompany each shipment of the Merck Compound to Rexahn.  Upon request, Rexahn shall provide Merck with a certificate of analysis
          covering each shipment of Rexahn Compound used in the Study.

       

      8.7           Changes to Manufacturing.  Each Party may make changes from time to time to its Compound or the Manufacturing Site, provided that such changes shall be in accordance with the Clinical Quality Agreement.

       

      8.8           Product

              Testing; Noncompliance.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        21

        
          

      

      8.8.1          After Manufacturer’s Release.  After Manufacturer’s Release of the Merck Compound and concurrently with Delivery of the Compound to Rexahn, Merck shall provide Rexahn with such certificates
          and documentation as are described in the Clinical Quality Agreement.  Rexahn shall, within the time defined in the Clinical Quality Agreement, perform, with respect to the Merck Compound, the acceptance (including testing) procedures allocated
          to it under the Clinical Quality Agreement.  Subject to Section 2.3.2, Rexahn shall be responsible for taking all steps necessary to determine that Merck
          Compound or Rexahn Compound, as applicable, is suitable for release before making such Merck Compound or Rexahn Compound, as applicable, available for human use, and Merck shall provide cooperation or assistance as reasonably requested by Rexahn
          in connection with such determination with respect to the Merck Compound.  Rexahn shall be responsible for storage and maintenance of the Merck Compound until it is tested and/or released, which storage and maintenance shall be in compliance with
          (a) the Specifications for the Merck Compound, the Clinical Quality Agreement and Applicable Law and (b) any written specific storage and maintenance requirements as may be provided by Merck from time to time.  Rexahn shall be responsible for any
          failure of the Merck Compound to meet the Specifications to the extent caused by shipping, storage or handling conditions after Delivery to Rexahn hereunder.

       

      8.8.2          Non-Conformance.

       

      (a)             In the event that either
          Party becomes aware that any Compound may have a Non-Conformance, despite testing and quality assurance activities (including any activities conducted by the Parties under Section

              8.8.1), such Party shall immediately notify the other Party in accordance with the procedures of the Clinical Quality Agreement.  The Parties shall investigate any Non-Conformance in accordance with Section 8.9 (Investigations) and any discrepancy between them shall be resolved in accordance with Section
              8.8.3.

       

      (b)             In the event that any
          proposed or actual shipment of the Merck Compound (or portion thereof) shall be agreed or determined to have a Non-Conformance at the time of Delivery to Rexahn, then unless otherwise agreed to by the Parties, Merck shall replace such Merck
          Compound as is found to have a Non-Conformance (with respect to Merck Compound that has not yet been administered in the course of performing the Study).  Unless otherwise agreed to by the Parties in writing, the sole and exclusive remedies of
          Rexahn with respect to any Merck Compound that is found to have a Non-Conformance at the time of Delivery shall be (i) [***] provided that, for
          clarity, Rexahn shall not be deemed to be waiving any rights under Section 8.15.  In the event Merck Compound is lost or damaged by Rexahn after Delivery,
          Merck shall provide additional Merck Compound (if available for the Study) to Rexahn; provided that Rexahn shall [***] of such replaced Merck
          Compound; and provided further that Merck shall have no obligation to [***].  Except as set forth in the foregoing sentence, Merck shall have no
          obligation to provide replacement Merck Compound for any Merck Compound supplied hereunder other than such Merck Compound as has been agreed or determined to have a Non-Conformance at the time of Delivery to Rexahn.

       

      (c)             Rexahn shall be responsible
          for, and Merck shall have no obligation or liability with respect to, any Rexahn Compound supplied hereunder that is found to have a Non-Conformance.  Rexahn shall replace any Rexahn Compound as is found to have a Non-Conformance (with respect to
          Rexahn Compound that has not yet been administered in the course of performing the Study).  Unless otherwise agreed to by the Parties in writing, the sole and exclusive remedies of Merck with respect to any Rexahn Compound that is found to have a
          Non-Conformance at the time of Delivery shall be (i) [***], (ii) [***], and (iii) [***] provided that, for clarity, Merck shall not be deemed to be waiving any rights under Section 8.15.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        22

        
          

      

      

      8.8.3          Resolution of Discrepancies.  Disagreements regarding any determination of Non-Conformance by Rexahn shall be resolved in accordance with the provisions of the Clinical Quality Agreement.

       

      8.9           Investigations.  The process for investigations of any Non-Conformance shall be handled in accordance with the Clinical Quality Agreement.

       

      8.10         Shortage; Allocation.  In the event that a Party’s Compound is in short supply such that a Party reasonably believes in good faith that it will not be able to fulfill its supply
          obligations hereunder with respect to its Compound, such Party will provide prompt written notice to the other Party thereof (including the shipments of Compound hereunder expected to be impacted and the quantity of its Compound that such Party
          reasonably determines it will be able to supply) and the Parties will promptly discuss such situation (including how the quantity of Compound that such Party is able to supply hereunder will be allocated within the Study).  In such event, the
          Party experiencing such shortage shall (i) use its commercially reasonable efforts to remedy the situation giving rise to such shortage and to take action to minimize the impact of the shortage on the Study, and (ii) [***].

       

      8.11         Records; Audit Rights.  Rexahn shall maintain complete and accurate records pertaining to its use and disposition of Merck Compound (including its storage, shipping (cold chain) and chain
          of custody activities) and, upon request of Merck, shall make such records open to review by Merck for the purpose of conducting investigations for the determination of Merck Compound safety and/or efficacy and Rexahn’s compliance with this
          Agreement with respect to the Merck Compound.

       

      8.12         Quality.  Quality matters related to the Manufacture of the Compounds shall be governed by the terms of the Clinical Quality Agreement in addition to the relevant quality provisions of
          this Agreement.

       

      8.13         Quality Control.  Each Party shall implement and perform operating procedures and controls for sampling, stability and other testing of its Compound, and for validation, documentation and
          release of its Compound and such other quality assurance and quality control procedures as are required by the Specifications, cGMPs and the Clinical Quality Agreement.

       

      8.14         Audits and Inspections.  The Parties’ audit and inspection rights related to this Agreement shall be governed by the terms of the Clinical Quality Agreement.

       

      8.15         Recalls.  Recalls of the Compounds shall be governed by the terms of the Clinical Quality Agreement.

       

      8.16         VAT.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      

      
        23

        
          

      

      

      8.16.1        It is understood and agreed
          between the Parties that any payments made and any other consideration given under this Agreement are each exclusive of any value added or similar tax (“VAT”),

          which shall be added thereon as applicable and at the relevant rate.  Subject to Section 8.16.1, where VAT is properly charged by the supplying Party and
          added to a payment made or other consideration provided (as applicable) under this Agreement, the Party making the payment or providing the other consideration (as applicable) will pay the amount of VAT properly chargeable only on receipt of a
          valid tax invoice from the supplying Party issued in accordance with the laws and regulations of the country in which the VAT is chargeable.  Each Party agrees that it shall provide to the other Party any information and copies of any documents
          within its Control to the extent reasonably requested by the other Party for the purposes of (i) determining the amount of VAT chargeable on any supply made under this Agreement, (ii) establishing the place of supply for VAT purposes, or (iii)
          complying with its VAT reporting or accounting obligations.

       

      8.16.2        Where one Party or its
          Affiliate (the “First Party”) is treated as making supply of goods or services in a particular jurisdiction (for VAT purposes) for no
          consideration, and the other Party or its Affiliate (the “Second Party”) is treated as receiving such supply in the same jurisdiction, thus
          resulting in an amount of VAT being properly chargeable on such supply, the Second Party shall only be obliged to pay to the First Party the amount of VAT properly chargeable on such supply (and no other amount). The Second Party shall pay such
          VAT to the First Party on receipt of a valid VAT invoice from the First Party (issued in accordance with the laws and regulations of the jurisdiction in which the VAT is properly chargeable). Each Party agrees to (i) use its reasonable efforts to
          determine and agree the value of the supply that has been made and, as a result, the corresponding amount of VAT that is properly chargeable and (ii) provide to the other Party any information or copies of documents in its Control as are
          reasonably necessary to evidence that such supply will take, or has taken, place in the same jurisdiction (for VAT purposes).

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        24

        
          

      

      

      9.             Confidentiality.

       

      9.1           Confidential Information.  Subject to Sections 3.8 and 13.4.8, Rexahn and Merck agree to hold in confidence any Confidential Information provided by or on behalf of the other Party, and neither Party shall use Confidential Information of the other Party
          except to fulfill such Party’s obligations under this Agreement or exercising its rights.  Without limiting the foregoing, the Receiving Party may not, without the prior written permission of the Disclosing Party, disclose any Confidential
          Information of the Disclosing Party to any Third Party except to the extent disclosure (i) is required by Applicable Law; (ii) is pursuant to the terms of this Agreement; or (iii) is necessary for the conduct of the Study, and in each case ((i)
          through (iii)) provided that the Receiving Party shall provide reasonable advance notice to the Disclosing Party before making such disclosure. 
          For the avoidance of doubt, Rexahn may, without Merck’s consent, disclose Confidential Information to clinical trial sites and clinical trial investigators performing the Study, Subcontractors, the data safety monitoring and advisory board
          relating to the Study, and Regulatory Authorities working with Rexahn on the Study, in each case to the extent necessary for the performance of the Study and provided that such Persons (other than governmental entities) are bound by an obligation of confidentiality at least as stringent as the obligations contained herein.

       

      9.2           Inventions.  Notwithstanding the foregoing: (i) Inventions that constitute Confidential Information and are jointly owned by the Parties, shall constitute the Confidential Information of
          both Parties and each Party shall have the right to use and disclose such Confidential Information consistent with Articles 10, 11 and 12; and (ii) Inventions that constitute Confidential Information and are solely owned by one
          Party shall constitute the Confidential Information of that Party and each Party shall have the right to use and disclose such Confidential Information consistent with Articles

              10, 11 and 12.

       

      9.3           Personal Identifiable Data.  All Confidential Information containing personal identifiable data shall be handled in accordance with all data protection and privacy laws, rules and
          regulations applicable to such data.

       

      The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties, subject to the exceptions in Section 9.1 and Section 9.2.

       

      10.           Intellectual

              Property.

       

      10.1         [***].

       

      (d)            Except as expressly provided
          in Section 10.1.1(c) and in furtherance and not in limitation of Section 9.1,
          each Party agrees to make no Patent Application based on the other Party’s Confidential Information, and to give no assistance to any Third Party for such application, without the other Party’s prior written authorization.

       

      10.1.2       Patent Enforcement.

       

      

      [***] INDICATES MORE THAN ONE PAGE OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED
          MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      

      
        25

        
          

      

      (a)             Each Party shall promptly
          notify the other in writing of any actual or threatened infringement or misappropriation by a Third Party of any [***] of which such Party becomes aware (“Third

            Party Infringement”).

       

      (b)             Rexahn shall have the first
          right to initiate legal action to enforce all [***].  In the event that Rexahn fails to initiate or defend such action by the earlier of (i) [***] after first being notified or made aware of such Third Party Infringement and (ii) [***] before the
          expiration for initiating or defending such action, Merck shall have the right to initiate or defend such action at its sole expense.

       

      (c)             Merck shall have the first
          right to initiate legal action to enforce all [***].  In the event that Merck fails to initiate or defend such action by the earlier of (i) [***] after first being notified or made aware of such Third Party Infringement and (ii) [***] before the
          expiration for initiating or defending such action, Rexahn shall have the right to do so at its sole expense.

       

      (d)             The Parties shall cooperate
          in good faith to jointly control legal action to enforce all [***] against any Third Party Infringement where such Third Party Infringement results from the development or sale of a product(s) that [***]. Notwithstanding the foregoing, either
          Party shall have the right to opt-out of controlling such legal action by providing written notice to the other Party by the earliest of (1) [***] after first being noticed of such Third Party Infringement, (2) [***] before the expiration date
          for filing such action, (3) [***] before the expiration date for filing an answer to a complaint in a declaratory judgment action, and (4) [***] after receipt of an application to the FDA under Section 351(k) of the U.S. Public Health Services
          Act (42 U.S.C. 262(k)), or to a similar agency under any similar provisions in another country, seeking approval of a biosimilar or interchangeable biological product of the Merck Compound, whichever comes first.

       

      (e)             If one Party brings any
          prosecution or enforcement action or proceeding against a Third Party with respect to [***] the second Party agrees to be joined as a party plaintiff where necessary and to give the first Party reasonable assistance and authority to file and
          prosecute the suit.  The costs and expenses of the Party bringing suit under this Section 10.1.2 shall be borne by such Party, and any damages or other
          monetary awards recovered relating to [***] shall be [***]. A settlement or consent judgment or other voluntary final disposition of a suit under this Section 10.1.2
          may not be entered into without the consent of the Party not bringing the suit.

       

      10.2         Inventions Owned by Rexahn.  Notwithstanding anything to the contrary contained in Section 10.1,
          the Parties agree that all rights to Inventions relating solely to, or covering solely, the Rexahn Compound [***] are the exclusive property of Rexahn (“Rexahn

            Inventions”).  Rexahn shall (a) be entitled to file and prosecute in its own name Patent Applications in respect of Rexahn Inventions and (b) own Patents that issue from any such Patent Applications in respect of Rexahn Inventions. 
          [***] Merck hereby assigns its right, title and interest to any and all Rexahn Inventions to Rexahn.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        26

        
          

      

      10.3         Inventions Owned by Merck.  Notwithstanding anything to the contrary contained in Section 10.1, the
          Parties agree that all rights to Inventions relating solely to, or covering solely, the Merck Compound [***] are the exclusive property of Merck (“Merck
            Inventions”).  Merck shall (a) be entitled to file and prosecute in its own name Patent Applications in respect of Merck Inventions and (b) own Patents that issue from any such Patent Applications in respect of Merck Inventions. [***]
          Rexahn hereby assigns its right, title and interest to any and all Merck Inventions to Merck.

       

      10.4         Mutual Freedom to Operate for Combination Inventions.

       

      10.4.1        Rexahn License to Merck.  Rexahn hereby grants to Merck a non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license to any patent Controlled by Rexahn that
          [***] (the “Rexahn Background Patents”) solely for the purposes of: [***] provided, however, that in no event shall Merck or their assignee or sublicensee have the right to exploit Rexahn
          Background Patents to sell the Rexahn Compound or any Rexahn Class Compound, either alone or as part of a combination (including the Combination).

       

      10.4.2        Merck License to Rexahn.  Merck hereby grants to Rexahn a non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license to any patent Controlled by Merck that
          [***] (the “Merck Background Patents”) solely for the purposes of: [***] provided, however, that in no event shall Rexahn or their assignee or sublicensee have the right to exploit Merck
          Background Patents to sell the Merck Compound or any PD-1 Antagonist, either alone or as part of a combination (including the Combination).

       

       
      10.4.3        No Other Rights.  For clarity, the terms of this Section 10.4 do not provide Merck or Rexahn with any
          rights, title or interest or any license to the other Party’s intellectual property rights which [***].

       

      10.4.4        Termination.  Any and all licenses granted under this Section 10.4 shall terminate upon the expiration
          or earlier termination of this Agreement and shall not survive such expiration or termination; provided, however that [***] shall survive expiration of this Agreement.

       

      10.5         Ownership of Other Inventions. Ownership of all Inventions other than [***] Merck Inventions and Rexahn Inventions shall be based on inventorship as determined under United States patent
          law.

       

      
        
          11.           Reprints; Rights of Cross-Reference.

           

            

        

      

      Consistent with applicable copyright and other laws, each Party may use, refer to, and disseminate reprints of scientific,
          medical and other published articles and materials from journals, conferences and/or symposia relating to the Study that disclose the name of a Party, provided, however, that such use does not constitute an endorsement of any commercial product or service by the other Party.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        27

        
          

      

      

      12.           Publications;

              Press Releases.

       

      12.1         Clinical Trial Registry.  Rexahn shall register the Study with the Clinical Trials Registry located at www.clinicaltrials.gov and is committed to timely publication of the results
          following Study Completion, after taking appropriate action to secure intellectual property rights (if any) arising from the Study.  The publication of the results of the Study will be in accordance with the Protocol.

       

      12.2         Publication.  Each Party shall use reasonable efforts to publish or present scientific papers dealing with the Study in accordance with accepted scientific practice.  The Parties agree
          that prior to submission of the results of the Study for publication or presentation or any other dissemination of such results including oral dissemination, the publishing Party shall invite the other to comment on the content of the material to
          be published, presented, or otherwise disseminated according to the following procedure:

       

      12.2.1        At least [***] prior to
          submission for publication [***], the publishing Party shall provide to the other Party the full details of the proposed publication, presentation, or dissemination in an electronic version (cd-rom or email attachment).  Upon written request from
          the other Party, the publishing Party agrees not to submit data for publication/presentation/dissemination for an additional [***] in order to allow for actions to be taken to preserve rights for patent protection.

       

      12.2.2        The publishing Party shall
          give reasonable consideration to any request by the other Party made within the periods mentioned in Section 12.2.1 to modify the publication and the Parties
          shall work in good faith and in a timely manner to resolve any issue regarding the content for publication.

       

      12.2.3        The publishing Party shall
          remove all Confidential Information of the other Party before finalizing the publication.

       

      12.3         Press Releases.  Promptly following the Effective Date, Rexahn may issue the press release attached hereto as Exhibit C.  Unless otherwise required by Applicable Law or permitted under
          the terms of this Agreement, neither Party shall make any other public announcement concerning this Agreement without the prior written consent of the other Party.  To the extent a Party desires to make such public announcement that requires the
          prior written consent of the Party, such Party shall provide the other Party with a draft thereof [***] prior to the date on which such Party would like to make the public announcement[***].

       

      13.           Representations and Warranties; Disclaimers.

       

      13.1         Due Authorization.  Each of Rexahn and Merck represents and warrants to the other that: (a) it has the corporate power and authority and the legal right to enter into this Agreement and
          perform its obligations hereunder; (b) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (c) this Agreement has been
          duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms.

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        28

        
          

      

      13.2         Compounds.

       

      13.2.1        Rexahn Compound.  Rexahn hereby represents and warrants to Merck that: (a) Rexahn has the full right, power and authority to grant all of the
          licenses granted to Merck under this Agreement; and (b) Rexahn Controls the Rexahn Compound.

       

      13.2.2        Merck Compound.  Merck hereby represents and warrants to Rexahn that: (a) Merck has the full right, power and authority to grant all of the licenses granted to Rexahn under this Agreement; and
          (b) Merck Controls the Merck Compound.

       

      13.3         Results.  Rexahn does not undertake that the Study shall lead to any particular result, nor is the success of the Study guaranteed.  Neither Party shall be liable for any use that the
          other Party may make of the Clinical Data nor for advice or information given in connection therewith.

       

      13.4         Anti-Corruption

              and Anti-Bribery.

       

      13.4.1        In performing their
          respective obligations hereunder, the Parties acknowledge that the corporate policies of Rexahn and Merck and their respective Affiliates require that each Party’s business be conducted within the letter and spirit of the law. By signing this
          Agreement, each Party agrees to conduct the business contemplated herein in a manner that is consistent with all Applicable Law, including the Stark Act, Anti-Kickback Statute, Sunshine Act, and the U.S. Foreign Corrupt Practices Act, good
          business ethics, and its ethics and other corporate policies and agrees to abide by the spirit of the other Party’s guidelines, which may be provided by such other Party from time to time.

       

      13.4.2        Specifically, each Party
          represents and warrants that it has not, and covenants that it, its Affiliates, and its and its Affiliates’ directors, employees, officers, and anyone acting on its behalf, will not, in connection with the performance of this Agreement, directly
          or indirectly, make, promise, authorize, ratify or offer to make, or take any action in furtherance of, any payment or transfer of anything of value for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an
          improper advantage; or improperly assisting it in obtaining or retaining business for it or the other Party, or in any way with the purpose or effect of public or commercial bribery.

       

      13.4.3        Neither Party shall contact,
          or otherwise knowingly meet with, any Government Official for the purpose of discussing activities arising out of or in connection with this Agreement, without the prior written approval of the other Party, except where such meeting is consistent
          with the purpose and terms of this Agreement and in compliance with Applicable Law.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      
        29

        
          

      

      

      13.4.4        Each Party represents and
          warrants that it (a) is not excluded, debarred, suspended, proposed for suspension or debarment, in Violation or otherwise ineligible for government programs; and (b) has not employed or subcontracted with any Person for the performance of the
          Study who is excluded, debarred, suspended, proposed for suspension or debarment, or is in Violation or otherwise ineligible for government programs.

       

      13.4.5        Each Party represents and
          warrants that, except as disclosed to the other in writing prior to the Effective Date, such Party: (a) does not have any interest that directly or indirectly conflicts with its proper and ethical performance of this Agreement; (b) shall maintain
          arm’s length relations with all Third Parties with which it deals for or on behalf of the other in performance of this Agreement; and (c) has provided complete and accurate information and documentation to the other Party, the other Party’s
          Affiliates and its and their personnel in the course of any due diligence conducted by the other Party for this Agreement, including disclosure of any officers, employees, owners or Persons directly or indirectly retained by such Party in
          relation to the performance of this Agreement who are Government Officials or relatives of Government Officials.  Each Party shall make all further disclosures to the other Party as are necessary to ensure the information provided remains
          complete and accurate throughout the Term.  Subject to the foregoing, each Party agrees that it shall not hire or retain any Government Official to assist in its performance of this Agreement, with the sole exception of conduct of or
          participation in clinical trials under this Agreement, provided that such hiring or retention shall be subject to the completion by the hiring or
          retaining Party of a satisfactory anti-corruption and bribery (e.g., FCPA) due diligence review of such Government Official.  Each Party further covenants that any future information and documentation submitted to the other Party as part of
          further due diligence or a certification shall be complete and accurate.

       

      13.4.6        Each Party shall have the
          right during the Term, and for a period of [***] of this Agreement, to conduct an investigation and audit of the other Party’s activities, books and records, to the extent they relate to that other Party’s performance under this Agreement, to
          verify compliance with the terms of this Section 13.4.  [***]

       

      13.4.7        Each Party shall use
          commercially reasonable efforts to ensure that all transactions under the Agreement are properly and accurately recorded in all material respects on its books and records and that each document upon which entries in such books and records are
          based is complete and accurate in all material respects.  Each Party further represents, warrants and covenants that all books, records, invoices and other documents relating to payments and expenses under this Agreement are and shall be complete
          and accurate and reflect in reasonable detail the character and amount of transactions and expenditures.  Each Party shall maintain a system of internal accounting controls reasonably designed to ensure that no off-the-books or similar funds or
          accounts will be maintained or used in connection with this Agreement.

       

      13.4.8        Each Party agrees that in the
          event that the other Party believes in good faith that there has been a possible violation of any provision of Section 13.4, such other Party may make full
          disclosure of such belief and related information needed to support such belief at any time and for any reason to any competent government bodies and agencies, and to anyone else such Party determines in good faith has a legitimate need to know.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      
        30

        
          

      

      

      13.4.9        Each Party shall comply with
          its own ethical business practices policy and any corporate integrity agreement (if applicable) to which it is subject, and shall conduct its Study-related activities in accordance with Applicable Law.  Each Party shall ensure that all of its
          employees involved in performing its obligations under this Agreement are made specifically aware of the compliance requirements under this Section 13.4.  In
          addition, each Party shall ensure that all such employees participate in and complete mandatory compliance training to be conducted by each Party, including specific training on anti-bribery and corruption, prior to his/her performance of any
          obligations or activities under this Agreement.  Each Party shall certify its continuing compliance with the requirements under this Section 13.4 on a
          periodic basis during the Term in such form as may be reasonably specified by the other Party.

       

      13.4.10      Each Party shall have the
          right to terminate this Agreement immediately upon violation of this Section 13.4 in accordance with Section 6.6.

       

      13.5         DISCLAIMER.  EXCEPT AS EXPRESSLY PROVIDED HEREIN, MERCK MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF NON-INFRINGEMENT OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR
          PURPOSE, WITH RESPECT TO THE MERCK COMPOUND, AND REXAHN MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF NON-INFRINGEMENT OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE , WITH RESPECT TO THE REXAHN COMPOUND.

       

      
        
          14.           Insurance; Indemnification; Limitation of Liability.

           

            

        

      

      14.1         Insurance.  Each Party warrants that it maintains a policy or program of insurance or self-insurance at levels sufficient to support the indemnification obligations assumed herein.  Upon
          request, a Party shall provide evidence of such insurance.

       

      14.2         Indemnification.

       

      14.2.1      Indemnification by Rexahn.  Rexahn agrees to defend, indemnify and hold harmless Merck, its Affiliates, and its and their employees, directors, subcontractors and agents from and against any loss, damage,
          reasonable costs and expenses (including reasonable attorneys’ fees and expenses) incurred in connection with any claim, proceeding, or investigation by a Third Party arising out of this Agreement or the Study (a “Liability”), except to the extent that such Liability was directly caused by (a) negligence or willful misconduct on the part of Merck (or any of its Affiliates, or its and
          their employees, directors, subcontractors or agents); (b) a breach on the part of Merck of any of its representations and warranties or any other covenants or obligations of Merck under this Agreement; or (c) a breach of Applicable Law by Merck.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        31

        
          

      

      14.2.2        Indemnification by Merck.  Merck agrees to defend, indemnify and hold harmless Rexahn, its Affiliates, and
          its and their employees, directors, Subcontractors and agents from and against any Liability to the extent such Liability was directly caused by (a) negligence or willful misconduct on the part of Merck (or any of its Affiliates, or its and their
          employees, directors, Subcontractors or agents); (b) a breach on the part of Merck of any of its representations and warranties or any other covenants or obligations of Merck under this Agreement; or (c) a breach of Applicable Law by Merck.

       

      14.2.3        Procedure.  The obligations of Merck and Rexahn under this Section
              14.2 are conditioned upon the delivery of written notice to Merck or Rexahn, as the case might be, of any potential Liability within a reasonable time after a Party becomes aware of such potential Liability.  The indemnifying Party
          will have the right to assume the defense of any suit or claim related to the Liability (using counsel reasonably satisfactory to the indemnified Party) if it has assumed responsibility for the suit or claim in writing; provided that the indemnified Party may assume the responsibility for such defense to the extent the indemnifying Party does not do so in a timely manner).  The
          indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense.  The Party controlling such defense (the “Defending

            Party”) shall keep the other Party (the “Other Party”) advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the Other
          Party with respect thereto.  The Defending Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of the Other Party, which shall not be unreasonably withheld.  The Defending Party, but
          solely to the extent the Defending Party is also the indemnifying Party, shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional
          release of the Other Party from all liability with respect thereto or that imposes any liability or obligation on the Other Party without the prior written consent of the Other Party.

       

      14.2.4        Study Subjects.  Rexahn shall not offer compensation on behalf of Merck to any Study subject or bind Merck to any indemnification obligations in favor of any Study subject.  Merck shall not
          offer compensation on behalf of Rexahn to any Study subject or bind Rexahn to any indemnification obligations in favor of any Study subject.

       

      14.3         LIMITATION OF LIABILITY.  IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR SUBCONTRACTORS) BE LIABLE TO THE OTHER PARTY UNDER ANY THEORY FOR, NOR SHALL ANY INDEMNIFIED PARTY
          HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR OTHER SIMILAR DAMAGES OR ANY PUNITIVE DAMAGES OR ANY LOST PROFIT, LOST SALE OR LOST OPPORTUNITY DAMAGES (WHETHER SUCH CLAIMED DAMAGES ARE DIRECT OR INDIRECT), WHETHER
          ARISING DIRECTLY OR INDIRECTLY OUT OF (A) THE MANUFACTURE OR USE OF ANY COMPOUND SUPPLIED HEREUNDER OR (B) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT OR ANY REPRESENTATION, WARRANTY OR COVENANT CONTAINED IN OR
          MADE PURSUANT TO THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER OR WITH RESPECT TO DAMAGES
          ARISING OUT OF OR RELATED TO A PARTY’S BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT WITH RESPECT TO USE, DISCLOSURE, LICENSE, ASSIGNMENT OR OTHER TRANSFER OF [***].

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

       

        

      
        32

        
          

      

      

      
        
          15.           Use of Name.

        

      

       

        

      Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name
          or other designation of the other Party or any other trade name, trademark or logo of the other Party for any purpose in connection with the performance of this Agreement without the other Party’s prior written consent.

       

      
        
          16.           Force Majeure.

        

      

       

        

      If, in the performance of this Agreement, one of the Parties is prevented, hindered or delayed by reason of any cause beyond such
          Party’s reasonable control (e.g., war, riots, fire, strike, acts of terror, governmental laws), such Party shall be excused from performance to the extent that it is necessarily prevented, hindered or delayed (“Force Majeure”).  The non-performing Party shall notify the other Party of such Force Majeure [***] such occurrence by giving written notice to the other Party stating the nature of the
          event, its anticipated duration, and any action being taken to avoid or minimize its effect.  The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially
          reasonable efforts to remedy its inability to perform.

       

      
        
          17.           Entire Agreement; Amendment; Waiver.

        

      

       

        

      This Agreement, together with the Appendices and Schedules hereto and the Related Agreements, constitutes the sole, full and complete
          agreement by and between the Parties with respect to the subject matter of this Agreement, and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded by this Agreement.  In
          the event of a conflict between a Related Agreement and this Agreement, the terms of this Agreement shall control.  No amendments, changes, additions, deletions or modifications to or of this Agreement shall be valid unless reduced to writing and
          signed by the Parties hereto.  Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by
          or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other
          breach or failure by said other Party whether of a similar nature or otherwise.

       

      
        
          18.           Assignment and Affiliates.

           

            

        

      

      Neither Party shall assign or transfer this Agreement without the prior written consent of the other Party, such consent [***]; provided, however, that either Party may assign all or any part of
          this Agreement to one or more of its Affiliates without the other Party’s consent, and any and all rights and obligations of either Party may be exercised or performed by its Affiliates, provided that such Affiliates agree to be bound by this Agreement.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        33

        
          

      

      

      
        
          19.           Invalid Provision.

              

            

        

      

      If any provision of this Agreement is held to be illegal, invalid or unenforceable, the remaining provisions shall remain in full
          force and effect and will not be affected by the illegal, invalid or unenforceable provision. In lieu of the illegal, invalid or unenforceable provision, the Parties shall negotiate in good faith to agree upon a reasonable provision that is
          legal, valid and enforceable to carry out as nearly as practicable the original intention of the entire Agreement.

       

      
        
          20.           No Additional Obligations.

           

            

        

      

      Rexahn and Merck have no obligation to renew this Agreement or apply this Agreement to any clinical trial other than the Study. 
          Nothing in this Agreement obligates the Parties to enter into any other agreement (other than the Related Agreements) at this time or in the future.

       

      
        
          21.           Governing Law; Dispute Resolution.

           

            

        

      

      21.1         The Parties shall attempt in good faith to settle all disputes arising out of or in connection with this Agreement in an amicable manner.  Any claim, dispute or controversy arising out of or relating to this
          Agreement, including the breach, termination or validity hereof or thereof, shall be governed by and construed in accordance with the substantive laws of the State of New York, without giving effect to its choice of law principles.

       

      21.2         Nothing contained in this
          Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed or maintained
          notwithstanding any ongoing discussions between the Parties.

       

      
        
          22.           Notices.

           

            

        

      

      All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by
          facsimile (and promptly confirmed by personal delivery or overnight courier), or sent by internationally-recognized overnight courier addressed as follows:

       

      If to Rexahn, to:

       

      Rexahn Pharmaceuticals, Inc.

      15245 Shady Grove Road, Suite 455

      Rockville, MD 20850

      United States

      Attention:  Chief Executive Officer

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        34

        
          

      

      

      With a copy (which shall not constitute notice) to:

       

      Hogan Lovells US LLP

      100 International Drive

      Suite 2000

      Baltimore, MD 21202

      Attention:  Asher M. Rubin

       

      If to Merck, to:

       

      Merck Sharp & Dohme B.V.

      Waarderweg 39

      2031 BN Haarlem

      Netherlands

      Attention:  Director

      [***]

       

      With copies (which shall not constitute notice) to:

       

      Merck Sharp & Dohme Corp.

      One Merck Drive

      PO Box 100

      Whitehouse Station, NJ 08889-0100

      Attention:  Office of Secretary

       

        

      Merck Sharp & Dohme Corp.

      351 North Sumneytown Pike

      Mailstop UG4CD-16

      North Wales, PA 19454-2505

      Attention:  Senior Vice President, Research Science

       

        

      Merck Sharp & Dohme Corp.

      2000 Galloping Hill Road

      Mailstop K-1-3045

      Kenilworth, NJ 07033-1310

      Attention:  Assistant General Counsel, Corporate Transactions

       

      
        
          23.           Relationship of the Parties.

           

            

        

      

      The relationship between the Parties is and shall be that of independent contractors, and does not and shall not constitute a
          partnership, joint venture, agency or fiduciary relationship.  Neither Party shall have the authority to make any statements, representations or commitments of any kind, or take any actions, that are binding on the other Party, except with the
          prior written consent of the other Party to do so.  All Persons employed by a Party will be the employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account
          and expense of such Party.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        35

        
          

      

      

      
        
          24.           Counterparts and Due Execution.

           

            

        

      

      This Agreement and any amendment may be executed in any number of counterparts (including by way of facsimile or electronic
          transmission), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or
          printers.  When executed by the Parties, this Agreement shall constitute an original instrument, notwithstanding any electronic transmission, storage and printing of copies of this Agreement from computers or printers.  For clarity, facsimile
          signatures and signatures transmitted via PDF shall be treated as original signatures.

       

      
        
          25.           Construction.

              

            

        

      

      Except where the context otherwise requires, wherever used, the singular will include the plural, the plural the singular, the use of
          any gender will be applicable to all genders, and the word “or” is used in the inclusive sense (and/or).  Whenever this Agreement refers to a number of days,
          unless otherwise specified, such number refers to calendar days.  The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any
          provision contained in this Agreement.  The term “including” as used herein shall be deemed to be followed by the phrase “without limitation” or like expression.  The term “will” as used herein means shall.  The terms
          “hereof”, “hereto”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a
          whole and no to any particular provision of this Agreement. References to “Article,” “Section”, “Exhibit” or “Schedule” are
          references to the numbered sections of this Agreement and the appendices attached to this Agreement, unless expressly stated otherwise.  Except where the context otherwise requires, references to this “Agreement” shall include the appendices attached to this Agreement.  The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict
          construction will be applied against either Party hereto.

       

        

      [Remainder of page intentionally left blank.]

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        36

        
          

      

      IN WITNESS WHEREOF, the respective representatives of the Parties have executed this Agreement as of the Effective Date.

       

      

      	
              Rexahn Pharmaceuticals, Inc.

            	 
	 	 
	By:	
              /s/ Peter Suzdak

            	 
	 	 	 
	
              Peter Suzdak

            	 
	
              Name

            	 
	 	 
	
              CEO

            	 
	
              Title

            	 
	 	 
	
              8/13/18

            	 
	
              Date

            	 
	  	 
	
              Merck Sharp & Dohme B.V.

            	 
	 	 
	By:	
              /s/ K.J.F. Natland

            	 
	 	 	 
	
              K.J.F. Natland

            	 
	
              Name

            	 
	 	 
	
              Managing Director

            	 
	
              Title

            	 
	 	 
	
              16/8/18 (August)

            	 
	
              Date

            	 

      

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        37

        
          

      

      Exhibit A - PROTOCOL SYNOPSIS

       

      
        
          	Sponsor:	
                  Rexahn Pharmaceuticals, Inc.

                

        

      

       

      
        
          	Title:	
                  An Open Label Phase 2 Study of RX-5902 Administered in Combination With Pembrolizumab in Subjects with Metastatic Triple Negative Breast Cancer (TNBC)

                

        

      

       

      Protocol Number: RX5902-002 (KN-908)

       

      IND Number: TBD

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        38

        
          

      

      [***]

       

      

      [***] INDICATES 14 PAGES OF MATERIAL THAT WERE OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL
          WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        39

        
          

      

      Exhibit B - SUPPLY OF COMPOUND

       

        

      [***]

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        40

        
          

      

      Exhibit C – REXAHN PRESS RELEASE

       

      Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (SupinoxinTM) in combination with KEYTRUDA®
          (pembrolizumab) for Triple Negative Breast Cancer

       

      ROCKVILLE, MD --  --------, 2018 – Rexahn Pharmaceuticals, Inc.
          (NYSE American: RNN ), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD
          outside the United States and Canada) to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2
          trial in patients with metastatic triple negative breast cancer (TNBC).

       

      “Rexahn is excited to announce this collaboration with Merck, an established leader in the field of immuno-oncology,” said Peter D. Suzdak, Ph.D., chief
          executive officer of Rexahn. “RX-5902 has both antitumor and immune-modulatory effects and augments the efficacy of checkpoint inhibitors in animal models. Based on the mechanism of action of RX-5902 and our observations in preclinical studies,
          we are optimistic that the combination of RX-5902 with KEYTRUDA may provide meaningful clinical benefit in patients with metastatic triple negative breast cancer – a cancer that is notoriously difficult to treat”.

       

      The study will evaluate the safety and efficacy of the combination of RX-5902 and KEYTRUDA in patients with metastatic TNBC who have progressed following
          at least one prior treatment.  Under the terms of the agreement, Rexahn will sponsor the RX-5902 and KEYTRUDA study.

       

      KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

       

      About RX-5902

       

      RX-5902 (Supinoxin) is an orally administered, potential first-in-class, small molecule
            inhibitor of phosphorylated-p68(P-p68). P-p68, which is selectively overexpressed in cancer cells and is absent in normal tissue, modulates the activity of the β-catenin/Wnt pathway and plays a role in tumor progression, metastasis and
          tumor immunogenicity. 

       

      In preclinical studies, RX-5902 has been shown to inhibit the growth and proliferation of multiple human cancer cell lines (including triple negative
          breast cancer), decrease tumor growth in patient derived xenograft models and potentiate the activity of immune checkpoint inhibitors and other anti-tumor agents. RX-5902 is currently being evaluated as monotherapy in a Phase 2 clinical trial in
          patients with metastatic TNBC.  Preliminary data was presented at ASCO (American Society for Clinical Oncology) Annual Meeting in June 2018.  Additional information on RX-5902 can be found at: https://rexahn.com/cms/portfolio/rx-5902/.

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        41

        
          

      

      

      About Rexahn Pharmaceuticals, Inc.

       

      Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for
          the treatment of cancer. The company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally
          associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain
          of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The company
          has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0201. For more information about the Company and its oncology programs, please visit www.rexahn.com.

       

      Safe Harbor

       

      To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the
          Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products,
          enrollments in clinical trials, the path of clinical trials and development activities, and other statements identified by words such as “will,” “potential,” ““could,”“ “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,”
          “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be
          materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms
          and processes in cancer; drug candidates being in early stages of development, including clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain
          incentives provided by the U.S. Food and Drug Administration; the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications; and the expecting timing of
          results from our clinical trials. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual
          report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking
          statement, whether as a result of new information, future events or otherwise.

       

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

          

        

      

      
        42

        
          

      

      

      Media Contact:

      DGI Comm

      Susan Forman or Laura Radocaj

      +1-212-825-3210

      sforman@dgicomm.com

      lradocaj@dgicomm.com

       

      Investor contact:

      ir@rexahn.com

       

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        43

        
          

      

      Schedule I

       

      DATA SHARING AND SAMPLE TESTING SCHEDULE

       

        

      [***]

       

      [***] INDICATES TWO PAGES OF MATERIAL THAT WERE OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL
          WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      
        44

        
          

      

      Schedule 2.4

      REXAHN THIRD PARTIES

       

        

      [***]

         

      

      [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED
          SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

      

      

      

    

  

  45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]